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Materials and Methods.  Unless otherwise stated, reactions were performed in flame-
dried glassware under an inert atmosphere of argon or nitrogen using dry, deoxygenated 
solvents.  Reaction progress was monitored by thin-layer chromatography (TLC).  THF, 
Et2O, and CH2Cl2 were dried by passage through an activated alumina column under 
argon.  Triethylamine and diisopropylamine were distilled over CaH2 prior to use.  Brine 
solutions are saturated aqueous solutions of sodium chloride.  Allyl Mander’s reagents 
were prepared according to the method of Weber.[1]  Allyl 1H-imidazole-1-carboxylate 
reagents were prepared according to the method of Trost.[2]  Phosphinooxazoline 
(PHOX) ligands were prepared by methods described in our previous work.[3]  Tris(4,4’-
methoxydibenzylideneacetone)dipalladium(0) [Pd2(pmdba)3] was prepared according to 
the method of Ibers[4]or Fairlamb.[5]  All other reagents were purchased from Sigma-
Aldrich, Acros Organics, Strem, or Alfa Aesar and used as received unless otherwise 
stated.  Reaction temperatures were controlled by an IKAmag temperature modulator 
unless otherwise indicated.  Stirring was accomplished with Teflon® coated magnetic stir 
bars.  Glove box manipulations were performed under a N2 atmosphere.  TLC was 
performed using E. Merck silica gel 60 F254 precoated glass plates (0.25 mm) and 
visualized by UV fluorescence quenching or KMnO4 staining.  Silicycle SiliaFlash P60 
Academic Silica gel (particle size 0.040-0.063 mm) was used for flash column 
chromatography.  1H NMR spectra were recorded on a Varian Inova 500 MHz 
spectrometer or Varian Mercury 300 MHz spectrometer and are reported relative to 
residual CHCl3 (δ 7.26 ppm).  13C NMR spectra were recorded on a Varian Inova 500 
MHz (126 MHz) or Varian Mercury 300 MHz (75 MHz) spectrometer and are reported 
relative to CHCl3 (δ 77.16 ppm).  Data for 1H NMR are reported as follows: chemical 
shift (δ ppm) (multiplicity, coupling constant (Hz), integration).  Multiplicities are 
reported as follows: s = singlet, d = doublet, t = triplet, q = quartet, p = pentet, h = heptet, 
m = multiplet, br s = broad singlet, br d = broad doublet, app = apparent.  Data for 13C 
are reported in terms of chemical shifts (δ ppm).  IR spectra were obtained using a Perkin 
Elmer Spectrum BXII spectrometer using thin films deposited on NaCl plates and 
reported in frequency of absorption (cm–1).  Optical rotations were measured with a Jasco 
P-2000 polarimeter operating on the sodium D-line (589 nm) using a 100 mm path-length 
cell and are reported as: [α]D T (concentration in g/100 mL, solvent, ee).  High-resolution 
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mass spectra (HRMS) were obtained on an Agilent 6200 Series TOF with an Agilent 
G1978A Multimode source in electrospray ionization (ESI), atmospheric pressure 
chemical ionization (APCI), or mixed (MM: ESI-APCI) ionization mode. Syringe pump 
additions were performed using a KDS 100 syringe pump from KD Scientific. 
Preparative HPLC was accomplished using an Agilent 1200 Series HPLC with an Agilent 
Prep-SIL 30 x 250 mm column. Stereochemistry is assigned by analogy to previous 
results.[6] 
 
Representative Procedure 1 for the Preparation of 3-Oxopiperazine-2-
carboxylates and 1,4-Diazepane-2-carboxylates 
 
 
 
Piperazin-2-one (SI2) 
 
To a solution of ethylene diamine (3.34 mL, 50.0 mmol) in EtOH (39 mL) at 0 °C was 
added ethyl bromoacetate (SI1, 2.76 mL, 25.0 mol) dropwise.  The solution was warmed 
to 23 ºC and allowed to stir overnight open to the air.  The resulting white solid was 
removed by filtration, and the filtrate was transferred to a flame dried flask containing 
sodium ethoxide (3.74 g, 55.0 mmol) under a nitrogen atmosphere.  The solution was 
then heated to 80 °C and allowed to stir for 16 hours under nitrogen atmosphere.  The 
solution was cooled to room temperature and concentrated. Ketopiperazine (SI2) was 
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isolated by flash column chromatography (SiO2, 20% MeOH in CH2Cl2 to 25% MeOH in 
CH2Cl2) as a yellow solid.  64% yield.  Product identity was confirmed by comparison to 
previously reported characterization data. 
 
4-Benzylpiperazin-2-one (SI3) 
 
A 25 mL round bottom flask was charged with piperazin-2-one (SI2, 3.56 g, 36.3 mmol), 
triethylamine (8.1 mL, 58.1 mmol), benzyl bromide (3.88 mL, 32.7 mmol), and THF 
(360 mL) and allowed to stir for 16 hours at 23 ºC.  The reaction mixture was then 
concentrated and taken up in a saturated aqueous NaHCO3 solution.  The aqueous 
solution was extracted with EtOAc (5 x 50 mL) and the organic layers were concentrated 
to approximately 30 mL at which point SI3 precipitated from the solution.  The solid was 
collected by filtration and dried.  62% yield.  Product identity was confirmed by 
comparison to previously reported characterization data. 
 
1-Benzoyl-4-benzylpiperazin-2-one (SI4) 
 
Benzyl-protected ketopiperazine (SI3, 1.00 g, 5.26 mmol) was dissolved in 20 mL of 
THF warmed to 60 ºC and added by cannula to a freshly prepared solution of LDA (6.31 
mmol, prepared by the addition of 2.53 mL of 2.5 M nBuLi solution to a solution of 1.11 
mL of diisopropyl amine in 33 mL THF at 0 °C) cooled to –78 °C.  The reaction mixture 
was allowed to stir at –78 °C for 1.5 hours at which point benzoyl chloride (0.79 mL, 
8.84 mmol) was added dropwise.  The reaction was stirred at –78 °C for another 4 hours 
at which point full conversion of the starting material was observed by TLC analysis.  
The reaction mixture was warmed to 23 ºC and poured into 20 mL of H2O and extracted 
with EtOAc (4 x 20 mL).  The organics were combined, washed once with brine, dried 
HN
NBn
O
BzN
NBn
O
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with MgSO4, and concentrated under reduced pressure.  Ketopiperazine SI4 was isolated 
by flash column chromatography (SiO2, 20% EtOAc in hexanes to 25% EtOAc in 
hexanes) as a pale yellow solid.  83% yield.  Rf = 0.5 (35% EtOAc in hexanes); 1H NMR 
(500 MHz, CDCl3) δ 7.56 (dd, J = 8.3, 1.3 Hz, 2H), 7.53–7.45 (m, 1H), 7.44–7.28 (m, 
7H), 3.89–3.80 (m, 2H), 3.64 (s, 2H), 3.31 (s, 2H), 2.90–2.79 (m, 2H);	   13C NMR (126 
MHz, CDCl3) δ 173.8, 169.4, 136.5, 135.9, 131.9, 129.2, 128.7, 128.2, 128.1, 127.9, 
61.8, 58.9, 49.3, 45.2; IR (Neat Film, NaCl) 3062, 3027, 2958, 2903, 2809, 1708, 1683, 
1600, 1491, 1450, 1401, 1362, 1282, 1237, 1197, 1162, 1136, 1073, 950, 885, 795, 730 
cm–1; HRMS (MM: ESI-APCI) m/z calc'd for C18H19N2O2 [M+H]+: 295.1441, found 
295.1446. 
 
Allyl 4-benzoyl-1-benzyl-3-oxopiperazine-2-carboxylate (10a) 
 
Ketopiperazine (SI4, 1.40 g, 4.76 mmol) was dissolved in 25 mL of dry THF and added 
via cannula to a freshly prepared solution of LDA (5.71 mmol) in 23 mL dry THF at –78 
°C. The resulting dark red solution was allowed to stir at –78 °C for one hour at which 
point allyl cyanoformate (58.1 mg, 5.23 mmol) was added neat.  After 2.5 hours, the 
reaction reached completion according to TLC analysis.  The reaction mixture was 
warmed to 23 ºC and poured into 20 mL of H2O and then extracted with EtOAc (4 x 20 
mL).  The combined organics were washed once with brine, dried with MgSO4, and 
concentrated under reduced pressure.  Ketopiperazine 10a was isolated by flash column 
chromatography (SiO2, 10% EtOAc in hexanes) as a white solid.  63% yield.  Rf = 0.4 
(20% EtOAc in hexanes); 1H NMR (500 MHz, CDCl3) δ 7.64 (dd, J = 8.3, 1.2 Hz, 2H), 
7.53 – 7.45 (m, 1H), 7.41 – 7.33 (m, 5H), 7.31 (td, J = 8.6, 8.1, 3.9 Hz, 2H) 6.06–5.89 
(m, 1H), 5.40 (dd, J = 17.2, 1.4 Hz, 1H), 5.31 (dd, J = 10.4, 1.1 Hz, 1H), 4.73 (d, J = 6.0 
Hz, 2H), 4.17 (s, 1H), 3.93 (ddd, J = 12.5, 8.1, 4.3 Hz, 1H), 3.84 (d, J = 13.4 Hz, 1H), 
3.81–3.70 (m, 2H), 3.32 (ddd, J = 12.2, 8.1, 3.9 Hz, 1H), 2.80 (dt, J = 12.4, 5.0 Hz, 1H); 
13C NMR (126 MHz, CDCl3) δ 173.7, 167.7, 166.6, 136.5, 135.2, 132.2, 131.4, 129.1, 
128.7, 128.4, 128.3, 128.0, 119.7, 69.7, 66.6, 58.8, 45.0, 44.9; IR (Neat Film, NaCl) 
BzN
NBn
O O
O
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3062, 3029, 2846, 1733, 1690, 1600, 1583, 1494, 1450, 1368, 1281, 1232, 1154, 1091, 
1074, 985, 948, 945, 795, 731 cm–1; HRMS (MM: ESI-APCI) m/z calc'd for C22H23N2O4 
[M+H]+: 379.1652, found 379.1664. 
 
Allyl 4-benzoyl-1-benzyl-2-methyl-3-oxopiperazine-2-carboxylate (8b) 
Ketopiperazine (10a, 500.0 mg, 1.32 mmol) was dissolved in 8.8 mL of dry DMF along 
with Cs2CO3 (0.75 g, 2.31 mmol) and methyl iodide (90.0 µL, 1.45 mmol) and allowed to 
stir for 10.5 hours at 23 ºC.  The solution was then poured into 10 mL of H2O and 
extracted with EtOAc (4 x 10 mL).  The combined organics were washed once with 
brine, dried with MgSO4, and concentrated under reduced pressure. Acylated 
ketopiperazine 8b was isolated by flash column chromatography (SiO2, 15% EtOAc in 
hexanes to 20% EtOAc in hexanes) as a white solid.  35% yield.  Rf = 0.4 (20% EtOAc in 
hexanes); 1H NMR (300 MHz, CDCl3) δ 7.70–7.60 (m, 2H), 7.56–7.45 (m, 1H), 7.44–
7.34 (m, 6H), 7.34–7.27 (m, 1H), 6.01 (ddt, J = 17.1, 10.4, 6.0 Hz, 1H), 5.50–5.38 (m, 
1H), 5.34 (dq, J = 10.4, 1.1 Hz, 1H), 4.77 (dt, J = 6.0, 1.3 Hz, 2H), 4.01 (d, J = 14.0 Hz, 
1H), 3.91–3.66 (m, 2H), 3.43 (d, J = 14.0 Hz, 1H), 3.15 (ddd, J = 13.4, 9.3, 4.2 Hz, 1H), 
2.90 (dt, J = 12.6, 4.2 Hz, 1H), 1.78 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 173.9, 170.0, 
169.3, 137.9, 135.5, 132.0, 131.5, 128.7, 128.6, 128.3, 128.2, 127.8, 119.9, 71.4, 66.6, 
54.8, 44.9, 43.0, 20.2; IR (Neat Film, NaCl) 3062, 2943, 2848, 1741, 1685, 1600, 1495, 
1449, 1400, 1379, 1315, 1284, 1235, 1150, 1109, 928, 795, 723 cm–1; HRMS (MM: ESI-
APCI or EI+) m/z calc'd for C23H25N2O4 [M+H]+: 393.1809, found 393.1792. 
 
Allyl 1,4-dibenzoyl-2-methyl-3-oxopiperazine-2-carboxylate (8a) 
 
BzN
NBn
O O
O
Me
BzN
NBz
O O
O
Me
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Ketopiperazine 8a was prepared according to representative procedure 1, employing 
benzoyl chloride instead of benzyl bromide, and was isolated by flash column 
chromatography (SiO2, 15% EtOAc in hexanes to 25% EtOAc in hexanes) as a colorless 
solid.  Rf = 0.3 (20% EtOAc in hexanes); 1H NMR (500 MHz, CDCl3) δ 7.59–7.54 (m, 
2H), 7.54–7.49 (m, 2H), 7.49–7.45 (m, 4H), 7.41 (ddt, J = 7.8, 6.5, 1.0 Hz, 2H), 5.98 
(ddt, J = 17.2, 10.4, 5.8 Hz, 1H), 5.39 (dq, J = 17.2, 1.5 Hz, 1H), 5.28 (dq, J = 10.4, 1.2 
Hz, 1H), 4.81–4.70 (m, 2H), 4.20–4.06 (m, 2H), 4.00 (ddd, J = 14.1, 5.2, 3.6 Hz, 1H), 
3.73–3.63 (m, 1H), 1.99 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 172.3, 170.2, 169.1, 
167.3, 134.7, 134.6, 132.4, 131.7, 130.8, 129.0, 128.5, 127.9, 127.0, 119.0, 69.2, 67.2, 
44.6, 44.3, 19.6; IR (Neat Film, NaCl) 3583, 2943, 1762, 1700, 1690, 1647, 1600, 1448, 
1405, 1370, 1284, 1255, 1209, 1149, 1123, 991, 942, 789, 725 cm–1; HRMS (MM: ESI-
APCI or EI+) m/z calc'd for C23H23N2O5 [M+H]+: 407.1607, found 407.1600. 
 
Allyl 4-benzoyl-1-(4-methoxybenzyl)-2-methyl-3-oxopiperazine-2-carboxylate (8c) 
 
Ketopiperazine 8c was prepared according to representative procedure 1 employing 4-
methoxybenzyl chloride instead of benzyl bromide, and was isolated by flash column 
chromatography (SiO2, 10% EtOAc in hexanes to 20% EtOAc in hexanes) as a yellow 
oil.  Rf = 0.4 (20% EtOAc in hexanes); 1H NMR (500 MHz, CDCl3) δ 7.70–7.58 (m, 2H), 
7.54–7.44 (m, 1H), 7.43–7.33 (m, 2H), 7.30–7.21 (m, 2H), 6.94–6.84 (m, 2H), 6.01 (ddt, 
J = 16.4, 10.4, 6.0 Hz, 1H), 5.43 (dq, J = 17.2, 1.4 Hz, 1H), 5.34 (dq, J = 10.4, 1.1 Hz, 
1H), 4.82–4.72 (m, 2H), 3.90 (d, J = 13.7 Hz, 1H), 3.82 (s, 3H), 3.80 (t, J = 4.0 Hz, 1H), 
3.70 (ddd, J = 12.5, 9.8, 4.2 Hz, 1H), 3.32 (d, J = 13.7 Hz, 1H), 3.10 (ddd, J = 13.2, 9.8, 
3.7 Hz, 1H), 2.87 (dt, J = 12.6, 4.2 Hz, 1H), 1.75 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 
174.0, 170.4, 169.4, 159.2, 135.6, 132.0, 131.6, 130.2, 129.6, 128.2, 128.1, 119.8, 114.0, 
71.4, 66.5, 55.4, 54.1, 45.2, 42.7, 20.1; IR (Neat Film, NaCl) 3062, 2997, 2949, 2836, 
1742, 1687, 1611, 1512, 1465, 1449, 1378, 1285, 1245, 1171, 1150, 1108, 1034, 926, 825 
BzN
NPMB
O O
O
Me
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cm–1; HRMS (MM: ESI-APCI or EI+) m/z calc'd for C24H27N2O5 [M+H]+: 423.1914, 
found 423.1890. 
 
Allyl 1-benzyl-4-(4-fluorobenzoyl)-2-methyl-3-oxopiperazine-2-carboxylate (8d) 
 
Ketopiperazine 8d was prepared according to representative procedure 1 employing 4-
fluoro-benzoyl chloride instead of benzoyl chloride, and was isolated by flash column 
chromatography (SiO2, 15% EtOAc in hexanes) as a colorless solid.  Rf = 0.5 (20% 
EtOAc in hexanes); 1H NMR (500 MHz, CDCl3) δ 7.75–7.63 (m, 2H), 7.35 (d, J = 4.4 
Hz, 4H), 7.32–7.27 (m, 1H), 7.10–7.02 (m, 2H), 6.01 (ddt, J = 17.1, 10.4, 6.0 Hz, 1H), 
5.44 (dd, J = 17.2, 1.4 Hz, 1H), 5.36 (dd, J = 10.4, 1.1 Hz, 1H), 4.84–4.71 (m, 2H), 4.00 
(d, J = 14.0 Hz, 1H), 3.83–3.67 (m, 2H), 3.39 (d, J = 14.0 Hz, 1H), 3.10 (ddd, J = 13.5, 
9.6, 4.1 Hz, 1H), 2.88 (dt, J = 12.7, 4.1 Hz, 1H), 1.75 (s, 3H); 13C NMR (126 MHz, 
CDCl3) δ 172.9, 170.4, 169.4, 165.1 (d, 1JCF = 253.3 Hz), 138.3, 131.6 (d, 4JCF = 3.3 Hz), 
130.9 (d, 3JCF = 9.1 Hz), 128.7, 128.4, 127.7, 119.9, 115.5 (d, 2JCF = 22.2 Hz), 71.4, 66.5, 
54.7, 45.3, 43.0, 20.2; IR (Neat Film, NaCl) 3064, 3028, 3001, 2947, 2902, 2844, 1742, 
1689, 1601, 1509, 1454, 1409, 1379, 1316, 1283, 1235, 1150, 1110, 996, 928, 849, 765 
cm–1; HRMS (MM: ESI-APCI) m/z calc'd for C23H24FN2O4 [M+H]+: 411.1715, found 
411.1726. 
 
Allyl 1-benzyl-4-(4-methoxybenzoyl)-2-methyl-3-oxopiperazine-2-carboxylate (8e) 
 
Ketopiperazine 8e was prepared according to representative procedure 1 employing 4-
methoxy-benzoyl chloride instead of benzoyl chloride, and was isolated by flash column 
chromatography (SiO2, 20% EtOAc in hexanes) as a white solid.  Rf = 0.4 (30% EtOAc 
N
NBn
OO
F
O
O
Me
N
NBn
OO
MeO
O
O
Me
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in hexanes); 1H NMR (500 MHz, CDCl3) δ 7.74–7.65 (m, 2H), 7.39–7.32 (m, 4H), 7.29 
(ddt, J = 8.6, 5.5, 2.9 Hz, 1H), 6.91–6.83 (m, 2H), 6.02 (ddt, J = 16.4, 10.4, 6.0 Hz, 1H), 
5.44 (dq, J = 17.2, 1.3 Hz, 1H), 5.34 (dd, J = 10.4, 1.1 Hz, 1H), 4.77 (dt, J = 5.9, 1.2 Hz, 
2H), 3.98 (d, J = 14.0 Hz, 1H), 3.85 (s, 3H), 3.78–3.67 (m, 2H), 3.38 (d, J = 14.0 Hz, 
1H), 3.11 (ddd, J = 13.2, 8.4, 5.0 Hz, 1H), 2.87 (dt, J = 12.6, 4.1 Hz, 1H), 1.76 (s, 3H); 
13C NMR (126 MHz, CDCl3) δ 173.4, 170.1, 169.6, 163.1, 138.4, 131.7, 131.0, 128.7, 
128.4, 127.6, 127.4, 119.8, 113.6, 71.3, 66.5, 55.5, 54.8, 45.3, 43.0, 20.2; IR (Neat Film, 
NaCl) 3583, 2917, 2848, 1740, 1679, 1602, 1511, 1458, 1315, 1256, 1170, 1149, 1109, 
1026, 927, 843, 739 cm-1; HRMS (MM: ESI-APCI) m/z calc’d for C24H27N2O5 [M+H]+: 
423.1914, found 423.1879. 
 
Allyl 1-benzyl-4-(2-fluorobenzoyl)-2-methyl-3-oxopiperazine-2-carboxylate (8f) 
 
Ketopiperazine 8f was prepared according to representative procedure 1 employing 2-
fluoro-benzoyl chloride instead of benzoyl chloride, and was isolated by flash column 
chromatography (SiO2, 20% EtOAc in hexanes) as a yellow oil.  Rf = 0.4 (20% EtOAc in 
hexanes); 1H NMR (500 MHz, CDCl3) δ 7.49 (td, J = 7.4, 1.7 Hz, 1H), 7.43 (dddd, J = 
8.3, 7.2, 5.2, 1.8 Hz, 1H), 7.38–7.32 (m, 4H), 7.32–7.26 (m, 1H), 7.20 (td, J = 7.6, 1.0 
Hz, 1H), 7.04 (ddd, J = 10.1, 8.3, 0.8 Hz, 1H), 6.04–5.87 (m, 1H), 5.37 (dq, J = 17.2, 1.4 
Hz, 1H), 5.28 (dq, J = 10.4, 1.1 Hz, 1H), 4.83–4.60 (m, 2H), 3.99 (dt, J = 12.6, 4.0 Hz, 
1H), 3.89 (d, J = 14.0 Hz, 1H), 3.67 (ddd, J = 12.7, 9.5, 4.3 Hz, 1H), 3.37 (d, J = 14.0 Hz, 
1H), 3.14 (ddd, J = 13.0, 9.5, 3.7 Hz, 1H), 2.86 (dt, J = 12.7, 4.4 Hz, 1H), 1.75 (s, 3H); 
13C NMR (126 MHz, CDCl3) δ 170.7, 169.4, 168.6, 158.8 (d, 1JCF = 250.3 Hz), 138.2, 
132.6 (d, 4JCF = 8.5 Hz), 131.7, 129.5, 128.7, 128.5, 127.7, 125.4 (d, 3JCF = 14.6 Hz), 
124.4 (d, 5JCF = 3.4 Hz), 119.5, 115.6 (d, 2JCF = 21.6 Hz), 71.8, 66.5, 54.5, 44.7, 42.5, 
20.3; IR (Neat Film, NaCl) 3066, 3029, 2944, 2847, 1743, 1690, 1614, 1491, 1453, 1379, 
1301, 1230, 1146, 928, 755 cm-1; HRMS (MM: ESI-APCI) m/z calc’d for C23H24FN2O4 
[M+H]+: 411.1037, found 411.1715. 
N
NBn
OO O
O
Me
F
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3-Allyl 1-benzyl 4-benzyl-3-methyl-2-oxopiperazine-1,3-dicarboxylate (8g) 
 
Ketopiperazine 8g was prepared according to representative procedure 1 employing 
benzyl chloroformate instead of benzoyl chloride, and was isolated by flash column 
chromatography (SiO2, 10% EtOAc in hexanes to 20% EtOAc in hexanes) as a yellow 
oil.  Rf = 0.5 (20% EtOAc in hexanes); 1H NMR (500 MHz, CDCl3) δ 7.38–7.32 (m, 2H), 
7.32–7.25 (m, 2H), 7.25–7.21 (m, 5H), 7.21–7.16 (m, 1H), 5.86 (ddt, J = 17.1, 10.5, 5.8 
Hz, 1H), 5.30 (dq, J = 17.2, 1.5 Hz, 1H), 5.22 (d, J = 2.6 Hz, 2H), 5.18 (dq, J = 10.4, 1.2 
Hz, 1H), 4.74–4.55 (m, 2H), 3.78 (d, J = 14.0 Hz, 1H), 3.70 (dt, J = 12.2, 3.9 Hz, 1H), 
3.55–3.46 (m, 1H), 3.23 (d, J = 14.0 Hz, 1H), 2.97 (ddd, J = 13.1, 9.7, 3.7 Hz, 1H), 2.65 
(dt, J = 12.7, 4.3 Hz, 1H), 1.68 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 169.5, 168.9, 
153.6, 138.2, 135.3, 131.7, 128.7, 128.6, 128.5, 128.4, 128.2, 127.6, 119.2, 72.2, 68.9, 
66.2, 54.4, 46.2, 42.5, 20.9; IR (Neat Film, NaCl) 2944, 2848, 1779, 1723, 1495, 1456, 
1378, 1315, 1283, 1213, 1112, 1021, 995, 781, 739 cm-1; HRMS (MM: ESI-APCI) m/z 
calc’d for C24H27N2O5 [M+H]+: 423.1914, found 423.1913. 
 
Allyl 4-benzoyl-1-benzyl-2-ethyl-3-oxopiperazine-2-carboxylate (8h) 
 
Ketopiperazine 8h was prepared according to representative procedure 1 employing ethyl 
iodide instead of methyl iodide, and was isolated by flash column chromatography (SiO2, 
10% EtOAc in hexanes to 20% EtOAc in hexanes) as a yellow oil.  Rf = 0.6 (20% EtOAc 
in hexanes); 1H NMR (500 MHz, CDCl3) δ 7.71–7.63 (m, 2H), 7.53–7.46 (m, 1H), 7.42–
7.33 (m, 6H), 7.32–7.27 (m, 1H), 6.04 (ddt, J = 17.1, 10.4, 6.0 Hz, 1H), 5.46 (dq, J = 
17.2, 1.4 Hz, 1H), 5.37 (dq, J = 10.4, 1.1 Hz, 1H), 4.84–4.75 (m, 2H), 4.08 (d, J = 14.0 
Hz, 1H), 3.83 (dt, J = 12.6, 2.8 Hz, 1H), 3.69 (td, J = 12.2, 3.8 Hz, 1H), 3.29 (d, J = 14.0 
N
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Hz, 1H), 3.17 (td, J = 12.1, 3.1 Hz, 1H), 2.95 (ddd, J = 12.4, 3.6, 2.5 Hz, 1H), 2.30 (dq, J 
= 14.6, 7.3 Hz, 1H), 2.15 (dq, J = 14.7, 7.4 Hz, 1H), 1.04 (t, J = 7.3 Hz, 3H); 13C NMR 
(126 MHz, CDCl3) δ 174.1, 169.2, 169.0, 138.2, 135.7, 132.1, 131.7, 128.8, 128.4, 128.3, 
128.2, 127.6, 119.9, 75.0, 66.3, 54.5, 44.9, 43.0, 26.1, 8.4; IR (Neat Film, NaCl) 3063, 
3030, 2960, 2839, 1744, 1683, 1600, 1495, 1451, 1400, 1377, 1321, 1284, 1225, 1151, 
1119, 1082, 987, 962, 940, 796, 738, 720 cm-1; HRMS (MM: ESI-APCI) m/z calc’d for 
C24H27N2O4 [M+H]+: 407.1965, found 407.1950. 
 
 2-Phenylallyl 4-benzoyl-1-benzyl-2-methyl-3-oxopiperazine-2-carboxylate (8l) 
 
Ketopiperazine 8l was prepared according to representative procedure 1 starting from 
10d instead of 10a, and was isolated by flash column chromatography (SiO2, 15% EtOAc 
in hexaes) as a yellow oil.  Rf = 0.4 (15% EtOAc in hexanes) 1H NMR (500 MHz, CDCl3) 
δ 7.63 (dd, J = 8.2, 1.2 Hz, 2H), 7.56 – 7.44 (m, 3H), 7.42 – 7.35 (m, 4H), 7.35 – 7.30 (m, 
3H), 7.30 – 7.26 (m, 1H), 7.23 (d, J = 6.9 Hz, 2H), 5.63 (s, 1H), 5.57 – 5.44 (m, 1H), 5.32 
(dd, J = 12.9, 0.9 Hz, 1H), 5.15 – 4.99 (m, 1H), 3.87 (d, J = 14.0 Hz, 1H), 3.69 – 3.56 (m, 
2H), 3.12 (d, J = 14.0 Hz, 1H), 2.82 (ddd, J = 13.8, 9.5, 4.5 Hz, 1H), 2.67 (dt, J = 12.7, 
3.9 Hz, 1H), 1.72 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 173.9, 170.2, 169.5, 142.5, 
138.3, 138.0, 135.6, 131.9, 128.8, 128.6, 128.5, 128.3, 128.2, 128.1, 127.5, 126.4, 117.2, 
71.3, 67.3, 54.4, 45.1, 42.6, 20.6; IR (Neat Film, NaCl) 3060, 3029, 3001, 2944, 2900, 
2845, 1741, 1686, 1600, 1495, 1466, 1449, 1400, 1379, 1316, 1284, 1236, 1150, 1107, 
1028, 918, 780, 723 cm–1; HRMS (MM: ESI-APCI) m/z calc'd for C29H29N2O4 [M+H]+: 
469.2122, found 469.2122. 
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2-Chloroallyl 4-benzoyl-1-benzyl-2-methyl-3-oxopiperazine-2-carboxylate (8m) 
 
Ketopiperazine 8m was prepared according to representative procedure 1 starting from 
10c instead of 10a, and was isolated by flash column chromatography (SiO2, 5% EtOAc 
in hexanes to 10% EtOAc in hexanes) as a yellow oil. Rf = 0.4 (15% EtOAc in hexanes) 
1H NMR (500 MHz, CDCl3) δ 7.69 – 7.62 (m, 2H), 7.54 – 7.48 (m, 1H), 7.44 – 7.38 (m, 
2H), 7.38 – 7.34 (m, 4H), 7.34 – 7.28 (m, 1H), 5.59 (dt, J = 1.9, 1.0 Hz, 1H), 5.51 (d, J = 
1.9 Hz, 1H), 4.88 (d, J = 14.0 Hz, 1H), 4.80 (d, J = 13.3 Hz, 1H), 4.00 (d, J = 14.0 Hz, 
1H), 3.86 (dt, J = 12.4, 3.8 Hz, 1H), 3.73 (ddd, J = 12.4, 10.0, 4.1 Hz, 1H), 3.45 (d, J = 
14.0 Hz, 1H), 3.19 (ddd, J = 13.5, 10.0, 3.6 Hz, 1H), 2.91 (dt, J = 12.7, 4.1 Hz, 1H), 1.79 
(s, 3H); 13C NMR (126 MHz, CDCl3) δ 173.9, 170.1, 169.1, 138.3, 135.7, 135.4, 132.0, 
128.7, 128.5, 128.3, 128.2, 127.7, 116.9, 71.6, 67.4, 54.7, 45.2, 43.0, 20.5; IR (Neat Film, 
NaCl) 3062, 3029, 2946, 2846, 1746, 1686, 1639, 1600, 1495, 1450, 1401, 1379, 1316, 
1283, 1234, 1177, 1150, 1105, 1027, 1000, 971, 912, 724 cm–1; HRMS (MM: ESI-APCI) 
m/z calc'd for C23H24N2O4Cl [M+H]+: 427.1419, found 427.1420. 
 
Allyl 4-benzoyl-1-benzyl-2-methyl-3-oxo-1,4-diazepane-2-carboxylate (8o) 
 
1,4-Diazepane 8o was prepared according to representative procedure 1 employing 1,3-
diaminopropane instead of ethylene diamine, and was isolated by flash column 
chromatography (SiO2, 10% EtOAc in hexanes to 20% EtOAc in hexanes) as a colorless 
solid.  Rf = 0.7 (20% EtOAc in hexanes); 1H NMR (500 MHz, CDCl3) δ 7.65 (m, 2H), 
7.52 – 7.45 (m, 1H), 7.43–7.30 (m, 5H), 7.28 (m, 2H), 6.00 (ddt, J = 17.2, 10.4, 6.0 Hz, 
1H), 5.44 (dd, J = 17.2, 1.4 Hz, 1H), 5.33 (dd, J = 10.4, 1.4 Hz, 1H), 4.87–4.70 (m, 2H), 
4.29 (ddd, J = 14.4, 8.8, 3.0 Hz, 1H), 3.92 (ddd, J = 14.4, 6.1, 3.0 Hz, 1H), 3.77 (d, J = 
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14.2 Hz, 1H), 3.68 (d, J = 14.2 Hz, 1H), 3.44 (ddd, J = 15.4, 10.9, 4.9 Hz, 1H), 2.89 (ddd, 
J = 15.4, 6.1, 3.0 Hz, 1H), 1.79 (s, 3H), 1.78–1.73 (m, 1H), 1.69–1.62 (m, 1H); 13C NMR 
(126 MHz, CDCl3) δ 174.8, 173.7, 170.4, 139.3, 136.2, 131.9, 131.6, 128.6, 128.4, 128.3, 
128.1, 127.4, 119.8, 75.1, 66.5, 53.1, 46.8, 42.9, 26.9, 22.7; IR (Neat Film, NaCl) 3062, 
3028, 2945, 1742, 1682, 1600, 1494, 1450, 1377, 1357, 1281, 1256, 1139, 1104, 1024, 
947, 793, 740, 724 cm–1; HRMS (MM: ESI-APCI) m/z calc'd for C24H27N2O4 [M+H]+: 
407.1965, found 407.1966. 
 
Representative Procedure 2 for the Preparation of 3-oxopiperazine-2-
carboxylates 
 
N-Benzylalanine ethyl ester (SI7) 
 
D,L-Alanine (SI5, 1.50 g, 16.8 mmol) was dissolved in EtOH (100 mL) and cooled to 0 
°C.  Thionyl chloride (3.67 mL, 50.5 mmol) was then added dropwise and the resulting 
solution was heated to reflux for 5 hours.  The reaction mixture was then cooled to 23 ºC 
and excess thionyl chloride and ethanol were removed by rotary evaporation to yield 
HO
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EtOH
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alanine ethyl ester hydrogen chloride salt (SI6) which was used in the following step 
without further purification.  Alanine ester hydrogen chloride salt (SI6) was dissolved in 
MeOH (17 mL).  Then triethylamine (2.6 mL, 18.8 mmol) was added and the solution 
was allowed to stir for 15 minutes at which point benzaldehyde (1.74 mL, 17.1 mmol) 
was added neat.  The resulting solution was allowed to stir for 10 hours open to air.  Then 
the solution was cooled to 0 °C and NaBH4 (1.29 g, 34.1 mmol) was added portionwise. 
The mixture was allowed to stir overnight.  The reaction mixture was then carefully 
poured into 25 mL of 2 N HCl and was washed with Et2O (1 x 20 mL).  The aqueous 
layer was then basified with 2 N NaOH and was extracted with CH2Cl2 (4 x 40 mL).  The 
organic layers were combined and washed once with brine, dried with MgSO4, and 
concentrated under reduced pressure to give N-benzylalanine ethyl ester (SI7) in a 90% 
yield from alanine (SI5).  Product identity was confirmed by comparison to previously 
reported characterization data. 
 
4-Benzyl-3-methylpiperazin-2-one (SI9) 
 
A solution of N-(2-hydroxyethyl)phthalimide (SI8, 769 mg, 4.00 mmol) in CH2Cl2 (4 
mL) under argon atmosphere was cooled to 0 °C.  Triflic anhydride (0.81 mL, 4.82 
mmol) was added dropwise, and the resulting solution was allowed to stir for 10 minutes 
at 0°C. Then 2,6-lutidine (560 µL, 4.82 mmol) was added and allowed to stir for another 
10 minutes before triethylamine (670 µL, 4.82 mmol) and SI7 (suspended in 4 mL of 
CH2Cl2) were added sequentially in dropwise fashion. The solution was warmed to 23 ºC 
and allowed to stir overnight under Ar atmosphere.  The reaction mixture was diluted 
with additional CH2Cl2 and washed with 10% aqueous citric acid (2 x 10 mL).  The 
organics were dried with Na2SO4 and concentrated.  The resulting oil was taken up in 
MeOH (22 mL), hydrazine hydrate (0.45 mL, 9.20 mmol) was added, and the mixture 
was allowed to stir overnight.  The reaction mixture was filtered and the filtrate was 
concentrated under reduced pressure.  Ketopiperazine SI9 was isolated by flash column 
HN
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chromatography (SiO2, 3% MeOH in CH2Cl2 to 5% MeOH in CH2Cl2) as a yellow solid.  
54% yield.  Rf = 0.5 (10% MeOH in CH2Cl2); 1H NMR (500 MHz, CDCl3) δ 7.38–7.26 
(m, 5H), 6.02 (br s, 1H), 3.94 (d, J = 13.5 Hz, 1H), 3.42 (d, J = 13.5 Hz, 1H), 3.36–3.17 
(m, 3H), 2.91 (dt, J = 12.3, 4.8 Hz, 1H), 2.48 (ddd, J = 12.3, 7.4, 4.5 Hz, 1H), 1.48 (d, J = 
6.9 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 173.0, 138.2, 128.9, 128.5, 127.4, 60.3, 58.3, 
45.3, 41.2, 15.5; IR (Neat Film, NaCl) 3203, 3057, 2983, 2953, 2923, 2878, 2819, 1667, 
1495, 1451, 1345, 1303, 1147, 1088, 1072, 1051, 1024, 890, 822, 750 cm–1; HRMS 
(MM: ESI-APCI) m/z calc'd for C12H17N2O [M+H]+: 205.1335, found 205.1338. 
 
1-Benzoyl-4-benzyl-3-methylpiperazin-2-one (SI10) 
 
Ketopiperazine (SI9, 24.7 mg, 1.21 mmol) was dissolved in 6 mL of dry THF and added 
by cannula to a freshly prepared solution of LDA (1.45 mmol) in 6.1 mL dry THF at –78 
°C.  The reaction mixture was allowed to stir at –78 °C for 1.5 hours at which point 
benzoyl chloride (0.18 mL, 1.57 mmol) was added dropwise.  The reaction was stirred at 
–78 °C for another 4 hours at which point full conversion of the starting material was 
observed by TLC analysis.  The reaction mixture was warmed to room temperature and 
poured into 15 mL of H2O and extracted with EtOAc (4 x 20 mL).  The organics were 
combined and washed once with brine, dried with Na2SO4, and concentrated under 
reduced pressure.  Ketopiperazine SI10 was isolated by flash column chromatography 
(SiO2, 10% EtOAc in hexanes to 15% EtOAc in hexanes) as a colorless solid.  81% yield. 
Rf = 0.5 (30% EtOAc in hexanes); 1H NMR (500 MHz, CDCl3) δ 7.54 (app d, J = 7.3 Hz, 
2H), 7.52–7.45 (m, 1H), 7.44–7.33 (m, 6H), 7.34–7.27 (m, 1H), 3.99 (d, J = 13.5 Hz, 
1H), 3.95–3.83 (m, 1H), 3.77–3.59 (m, 1H), 3.46 (d, J = 13.5 Hz, 1H), 3.37 (app q, J = 
6.1 Hz, 1H), 3.18–3.01 (m, 1H), 2.73–2.51 (m, 1H), 1.55 (s, 3H); 13C NMR (126 MHz, 
CDCl3) δ 173.9, 173.5, 136.0, 131.8, 129.9, 129.0, 128.7, 128.3, 128.0, 127.7, 62.3, 58.3, 
46.0, 44.7, 15.7; IR (Neat Film, NaCl) 3085, 3062, 3029, 2979, 2942, 2898, 2814, 1693, 
1600, 1583, 1455, 1367, 1286, 1228, 1145, 1096, 1075, 1027, 978, 945, 896, 872, 795, 
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749 cm–1; HRMS (MM: ESI-APCI) m/z calc'd for C19H21N2O2 [M+H]+: 309.1598, found 
309.1599. 
 
Allyl 4-benzoyl-1-benzyl-2-methyl-3-oxopiperazine-2-carboxylate (8b) 
 
To a cooled solution of KHMDS (64.0 g, 3.19 mmol) in THF (20 mL) at –78 ºC was 
added a solution of ketopiperazine (SI10, 89.0 g, 2.90 mmol) in THF (10 mL) over a 
period of 6.5 hours by syringe pump.  The resulting solution was allowed to stir for an 
additional 30 minutes at which point allyl cyanoformate (39.0 g, 3.48 mmol) was added 
neat.  The reaction mixture was stirred at –78 °C for 2 hours at which point full 
conversion of the starting material was observed by TLC analysis.  The reaction mixture 
was warmed to 23 ºC, poured into 15 mL of H2O, and extracted with EtOAc (4 x 20 mL).  
The organics were combined, washed once with brine, dried with Na2SO4, and 
concentrated under reduced pressure.  Ketopiperazine 8b was isolated by flash column 
chromatography (SiO2, 15% EtOAc in hexanes to 20% EtOAc in hexanes) as a light 
yellow solid.  61% yield.  Product identity was confirmed by comparison to 
characterization data reported above. 
 
Allyl 4-benzoyl-1-benzyl-2-isobutyl-3-oxopiperazine-2-carboxylate (8i) 
 
Ketopiperazine 8i was prepared according to representative procedure 2 starting from 
D,L-leucine instead of D,L-alanine, and was isolated by flash column chromatography 
(SiO2, 10% Et2O in hexanes to 15% Et2O in hexanes) as a white solid.  Rf = 0.4 (20% 
Et2O in hexanes); 1H NMR (500 MHz, CDCl3) δ 7.72–7.65 (m, 2H), 7.53–7.46 (m, 1H), 
7.41–7.32 (m, 6H), 7.32–7.27 (m, 1H), 6.05 (ddt, J = 17.1, 10.4, 6.0 Hz, 1H), 5.46 (dq, J 
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= 17.1, 1.4 Hz, 1H), 5.38 (dq, J = 10.4, 1.4 Hz, 1H), 4.85–4.76 (m, 2H), 4.11 (d, J = 14.0 
Hz, 1H), 3.86–3.71 (m, 2H), 3.23 (d, J = 14.0 Hz, 1H), 3.15 (ddd, J = 12.4, 10.1, 5.1 Hz, 
1H), 2.95 (dt, J = 12.4, 3.0 Hz, 1H), 2.28 (dd, J = 15.0, 4.3 Hz, 1H), 2.18 (dd, J = 15.0, 
9.3 Hz, 1H), 2.04 (ddtd, J = 10.1, 9.3, 6.7, 4.3 Hz, 1H), 0.98 (d, J = 6.7 Hz, 3H), 0.86 (d, 
J = 6.7 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 174.4, 169.0, 168.8, 137.9, 135.6, 132.1, 
131.7, 128.8, 128.5, 128.3, 128.1, 127.6, 120.0, 73.8, 66.4, 54.8, 45.0, 43.0, 40.2, 24.7, 
23.8, 22.4; IR (Neat Film, NaCl) 3063, 3030, 2958, 2870, 1739, 1687, 1683, 1601, 1495, 
1451, 1368, 1317, 1284, 1227, 1151, 1107, 984, 935, 795, 767, 722 cm–1; HRMS (MM: 
ESI-APCI) m/z calc'd for C26H31N2O4 [M+H]+: 435.2278, found 435.2291. 
 
Allyl 4-benzoyl-1,2-dibenzyl-3-oxopiperazine-2-carboxylate (8j) 
 
Ketopiperazine 8j was prepared according to representative procedure 2 starting from 
D,L-phenylalanine instead of D,L-alanine, and was isolated by flash column 
chromatography (SiO2, 15% Et2O in hexanes) as a white solid.  Rf = 0.5 (30% Et2O in 
hexanes); 1H NMR (500 MHz, CDCl3) δ 7.53–7.44 (m, 3H), 7.40–7.32 (m, 4H), 7.29 
(app s, 6H), 7.22 (app d, J = 7.1 Hz, 2H), 6.07 (ddt, J = 17.2, 10.4, 6.0 Hz, 1H), 5.49 (dd, 
J = 17.2, 1.3 Hz, 1H), 5.39 (dd, J = 10.4, 1.3 Hz, 1H), 4.94–4.77 (m, 2H), 4.29 (d, J = 
13.8 Hz, 1H), 3.77–3.64 (m, 1H), 3.61 (d, J = 14.6 Hz, 1H), 3.44 (d, J = 14.6 Hz, 1H), 
3.32 (d, J = 13.8 Hz, 1H), 3.19–3.04 (m, 2H), 2.93–2.82 (m, 1H); 13C NMR (126 MHz, 
CDCl3) δ 173.6, 168.9, 168.6, 137.3, 135.9, 135.5, 132.1, 131.6, 131.0, 128.7, 128.7, 
128.4, 128.3, 128.1, 127.6, 127.1, 120.0, 75.5, 66.6, 54.5, 44.1, 43.1, 38.7; IR (Neat Film, 
NaCl) 3086, 3062, 3030, 2845, 1738, 1690, 1601, 1495, 1455, 1403, 1373, 1322, 1283, 
1242, 1218, 1102, 1029, 942, 860, 794, 771 cm–1; HRMS (MM: ESI-APCI) m/z calc'd for 
C29H29N2O4 [M+H]+: 469.2122, found 469.2133. 
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Allyl 4-benzoyl-1-benzyl-2-[(benzyloxy)methyl]-3-oxopiperazine-2-carboxylate (8k) 
 
Ketopiperazine 8k was prepared according to representative procedure 2 starting from O-
(phenylmethyl)-(L)-serine instead of D,L-alanine, and was isolated by flash column 
chromatography (SiO2, 10% EtOAc in hexanes) as a colorless solid.  Rf = 0.4 (20% 
EtOAc in hexanes) 1H NMR (500 MHz, CDCl3) δ 7.67 (m, 2H), 7.51–7.43 (m, 1H), 
7.42–7.36 (m, 4H), 7.36–7.27 (m, 8H), 5.96 (ddt, J = 17.1, 10.4, 6.0 Hz, 1H), 5.39 (dd, J 
= 17.1, 1.4 Hz, 1H), 5.35–5.27 (dd, J = 10.4, 1.4 Hz, 1H), 4.77–4.64 (m, 3H), 4.61 (d, J = 
12.2 Hz, 1H), 4.20 (d, J = 10.0 Hz, 1H), 4.07 (d, J = 10.0 Hz, 1H), 4.03–3.91 (m, 2H), 
3.81–3.66 (m, 1H), 3.50 (d, J = 14.0 Hz, 1H), 3.18 (ddd, J = 12.7, 9.5, 4.2 Hz, 1H), 3.10 
(dt, J = 12.2, 4.2 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 173.7, 168.7, 168.0, 138.3, 
137.9, 135.5, 132.0, 131.5, 128.7, 128.6, 128.4, 128.4, 128.1, 127.9, 127.8, 127.6, 119.8, 
74.7, 74.0, 71.4, 66.4, 54.4, 44.7, 43.5; IR (Neat Film, NaCl) 3062, 3027, 2938, 2853, 
1738, 1687, 1600, 1495, 1452, 1376, 1321, 1284, 1226, 1148, 1099, 1047, 973, 940, 795, 
743 cm–1; HRMS (MM: ESI-APCI) m/z calc'd for C30H31N2O5 [M+H]+: 499.2227, found 
499.2229. 
 
Allyl 2-benzoyl-1-oxooctahydro-9aH-pyrido[1,2-a]pyrazine-9a-carboxylate (8n) 
 
Bicycle 8n was prepared according to representative procedure 2 starting from pipecolic 
acid and omitting the benzyl protection operation, and was isolated by flash column 
chromatography (SiO2, 15% EtOAc and 1% NEt3 in hexanes) as a white solid.  Rf = 0.3 
(25% EtOAc in hexanes); 1H NMR (500 MHz, CDCl3) δ 7.68–7.59 (m, 2H), 7.51–7.44 
(m, 1H), 7.40–7.33 (m, 2H), 6.00 (ddt, J = 17.1, 10.4, 6.0 Hz, 1H), 5.41 (dd, J = 17.1, 1.4 
Hz, 1H), 5.34 (dd, J = 10.4, 1.4 Hz, 1H), 4.76 (dt, J = 6.0, 1.4 Hz, 2H), 4.04 (td, J = 11.9, 
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5.5 Hz, 1H), 3.66 (ddd, J = 12.6, 4.7, 2.9 Hz, 1H), 3.49 (ddd, J = 12.9, 11.9, 4.7 Hz, 1H), 
3.23–3.07 (m, 1H), 3.07–2.94 (m, 1H), 2.87–2.66 (m, 1H), 2.31–2.15 (m, 1H), 1.88 (m, 
1H), 1.75–1.47 (m, 4H); 13C NMR (126 MHz, CDCl3) δ 174.4, 169.9, 169.8, 135.7, 
131.9, 131.4, 128.2, 128.1, 120.0, 70.3, 66.4, 50.0, 47.2, 44.4, 31.3, 24.7, 20.6; IR (Neat 
Film, NaCl) 2940, 2860, 1721, 1683, 1600, 1449, 1382, 1355, 1283, 1244, 1150, 1124, 
987, 940, 726 cm–1; HRMS (MM: ESI-APCI) m/z calc'd for C19H23N2O4 [M+H]+: 
343.1652, found 343.1665. 
 
Procedure for the Preparation of Allyl 4-benzoyl-2-methyl-3-oxo-1-
phenylpiperazine-2-carboxylate (8p) 
 
 
Ethyl phenylalaninate (SI12) 
 
Ethyl 2-bromopropionate (SI11, 2 mL, 15.4 mmol) was taken up in acetonitrile (18 mL) 
along with aniline (1.17 mL, 12.8 mmol), potassium carbonate (3.37 g, 24.4 mmol), and 
potassium iodide (0.26 g, 0.12 mmol) and heated to reflux for 48 hours.  The reaction 
mixture was filtered and the filtrate concentrated.  Ethyl phenylalaninate (SI12) was 
isolated by flash column chromatography (SiO2, 20% EtOAc in hexanes) as a colorless 
solid. Rf= 0.6 (30% EtOAc in hexanes).  Product identity was confirmed by comparison 
to previously reported characterization data. 
EtO
O
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–78 °C, 1.5 h
2. BzCl
–78 °C, 4 h
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Me
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2. allyl cyanoformate
–78 °C, 4 h
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Allyl 4-benzoyl-2-methyl-3-oxo-1-phenylpiperazine-2-carboxylate (8p) 
 
Cyclization, benzoyl protection, and acylation were accomplished as described in 
representative procedure 2.  Ketopiperazine 8p was isolated by preparative HPLC (SiO2, 
20% EtOAc in hexanes) as a colorless solid.  Rf= 0.4 (10% EtOAc in hexanes); 1H NMR 
(500 MHz, CDCl3) δ 7.66 (m, 2H), 7.55–7.47 (m, 1H), 7.40 (app t, J = 7.7 Hz, 2H), 7.35–
7.27 (m, 2H), 7.12 (app t, J = 7.4 Hz, 1H), 7.10–7.03 (m, 2H), 5.85 (ddt, J = 17.2, 10.4, 
7.0 Hz, 1H), 5.30 (dd, J = 17.2, 1.4 Hz, 1H), 5.25 (dd, J = 10.4, 1.1 Hz, 1H), 4.63 (d, J = 
7.0 Hz, 2H), 4.10 (ddd, J = 10.8, 4.7, 2.8 Hz, 1H), 4.05–3.92 (m, 2H), 3.55–3.44 (m, 1H), 
1.71 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 173.4, 170.5, 169.7, 147.0, 135.4, 132.0, 
131.3, 129.1, 128.3, 128.1, 124.6, 123.8, 119.5, 71.9, 66.5, 46.2, 44.9, 21.7; IR (Neat 
Film, NaCl) 3061, 3028, 2945, 2903, 2862, 1743, 1693, 1599, 1495, 1450, 1398, 1373, 
1283, 1179, 1115, 1075, 961, 865, 842, 811, 724 cm–1; HRMS (MM: ESI-APCI) m/z 
calc'd for C22H23N2O4 [M+H]+: 379.1652, found 379.1656. 
 
Procedure for the Preparation of Allyl 4-benzoyl-1,2-dimethyl-3-
oxopiperazine-2-carboxylate (8q) 
 
 
 
 
BzN
NPh
O O
O
Me
EtO
O
Br
1. ethylene diamine
EtOH
2. NaOEt
EtOH
90 °C, 14 h
1.formaldehyde
MeOH/H2O
2. NaCNBH3
HN
NMe
O 1. LDA, THF
–78 °C, 1.5 h
2. BzCl
–78 °C, 4 h
BzN
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O O
O
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Me Me
Me
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–78 °C, 1.5 h
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–78 °C, 4 h
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3,4-Dimethylpiperazin-2-one (SI13) 
 
To a solution of ethylene diamine (4.0 mL, 60.0 mmol) in EtOH (23 mL) at 0 °C was 
added ethyl 2-bromopropionate (SI11, 3.89 mL, 30.0 mmol) dropwise.  The solution was 
warmed to 23 ºC and allowed to stir overnight open to air.  The resulting white solid was 
removed by filtration, and the filtrate was transferred to a flame-dried flask containing 
sodium ethoxide (4.49 g, 66.0 mmol).  The solution was then heated to 80 °C and 
allowed to stir for 16 hours.  The solution was cooled to 23 ºC and concentrated. Half of 
the material was then taken up in 13.2 mL of MeOH.  Formaldehyde (37%, 0.88 mL, 
10.0 mmmol) was then added and the mixture was allowed to stir for 12 hours at 23 ºC, at 
which point NaBH3CN (0.77 g, 12.2 mmol) was added and the mixture was allowed to 
stir overnight open to air.  N-methyl ketopiperazine SI13 was isolated as a colorless solid 
by flash chromatography (SiO2, 5% MeOH in CH2Cl2 to 20% MeOH in CH2Cl2).  49% 
yield.  Rf = 0.5 (20% MeOH in CH2Cl2); 1H NMR (500 MHz, CDCl3) δ 7.03 (br s, 1H), 
3.43 (td, J = 11.0, 10.5, 4.2 Hz, 1H), 3.32–3.10 (m, 1H), 2.87 (dt, J = 12.2, 3.9 Hz, 1H), 
2.85–2.79 (m, 1H), 2.51 (ddd, J = 12.1, 10.0, 4.0 Hz, 1H), 2.36 (s, 3H), 1.36 (d, J = 6.8 
Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 172.8, 62.6, 50.5, 43.3, 40.7, 15.5; IR (Neat 
Film, NaCl) 3194, 2986, 2951, 2903, 2846, 2799, 1660, 1495, 1455, 1418, 1354, 1316, 
1296, 1249, 1223, 1137, 1097, 1034, 893, 854, 826, 782 cm–1; HRMS (MM: ESI-APCI) 
m/z calc'd for C6H13N2O [M+H]+: 129.1022, found 129.1023. 
 
Allyl 4-benzoyl-1,2-dimethyl-3-oxopiperazine-2-carboxylate (8q) 
 
Benzoyl protection of and acylation were carried out as described in representative 
procedure 2.  Ketopiperazine 8q was isolated by flash column chromatography (SiO2, 
20% EtOAc in hexanes) as a colorless oil.  Rf = 0.5 (40% EtOAc in hexanes); 1H NMR 
HN
NMe
O
Me
BzN
NMe
O
Me
O
O
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(500 MHz, CDCl3) δ 7.68–7.58 (m, 2H), 7.53–7.43 (m, 1H), 7.42–7.32 (m, 2H), 5.97 
(ddt, J = 17.2, 10.4, 6.0 Hz, 1H), 5.40 (dd, J = 17.2, 1.4 Hz, 1H), 5.31 (dd, J = 10.4, 1.1 
Hz, 1H), 4.79–4.66 (m, 2H), 3.93–3.82 (m, 2H), 3.28 (ddd, J = 12.7, 8.4, 5.5 Hz, 1H), 
2.94 (app dt, J = 12.6, 4.2 Hz, 1H), 2.43 (s, 3H), 1.60 (s, 3H);	   13C NMR (126 MHz, 
CDCl3) δ 174.0, 170.3, 169.0, 135.5, 132.0, 131.6, 128.2, 128.1, 119.7, 71.2, 66.4, 47.3, 
44.6, 39.1, 19.5; IR (Neat Film, NaCl) 3062, 2994, 2950, 2900, 2811, 1742, 1691, 1601, 
1450, 1398, 1372, 1315, 1275, 1219, 1153, 1109, 1046, 929, 887, 795, 754, 724 cm–1; 
HRMS (MM: ESI-APCI) m/z calc'd for C17H20N2O4Na [M+Na]+: 339.1315, found 
339.1320. 
 
Procedure for the Preparation of 2-Substituted allyl 4-benzoyl-1-benzyl-
3-oxopiperazine-2-carboxylates 
 
2-Methylallyl 4-benzoyl-1-benzyl-3-oxopiperazine-2-carboxylate (10b) 
LiHMDS (120 mg, 0.61 mmol) was suspended in 1.5 mL of THF and cooled to –78 °C. 
Then ketopiperazine (SI4, 150 mg, 0.51 mmol) dissolved in THF (600 µL) was added 
dropwise to the LiHMDS solution and allowed to stir at –78 °C for 30 minutes, at which 
point 2-methylallyl 1H-imidazole-1-carboxylate (110 mg, 0.66 mmol) dissolved in 0.5 
mL of THF was added dropwise.  The reaction mixture was allowed to stir for 6 hours at 
–78 °C at which point full conversion of the starting material was observed by TLC 
analysis.  The reaction mixture was then warmed to 23 ºC and poured into 5 mL of water.  
The aqueous layer was extracted with EtOAc (4 x 10 mL), the combined organics washed 
with brine (1 x 10 mL), and dried with Na2SO4.  2-Methylallyl 4-benzoyl-1-benzyl-3-
oxopiperazine-2-carboxylate (10b) was isolated as a yellow oil by flash column 
chromatography (SiO2, 20% EtOAc in hexanes).  14% yield.  Rf = 0.3 (20% EtOAc in 
hexanes); 1H NMR (500 MHz, CDCl3) δ 7.69–7.58 (m, 2H), 7.49 (tt, J = 7.1, 1.2 Hz, 
1H), 7.42–7.34 (m, 6H), 7.33–7.27 (m, 1H), 5.03 (d, J = 31.1 Hz, 2H), 4.66 (s, 2H), 4.19 
BzN
NBn
O
O
O
Me
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(s, 1H), 3.94 (ddd, J = 12.6, 8.3, 4.3 Hz, 1H), 3.89–3.78 (m, 2H), 3.76 (ddd, J = 12.6, 5.6, 
4.0 Hz, 1H), 3.33 (ddd, J = 12.4, 8.3, 3.9 Hz, 1H), 2.82 (dt, J = 12.4, 4.8 Hz, 1H), 1.78 (s, 
3H); 13C NMR (126 MHz, CDCl3) δ 173.8, 167.8, 166.6, 139.2, 136.5, 135.3, 132.2, 
129.1, 128.7, 128.4, 128.3, 128.0, 114.5, 69.6, 69.2, 58.7, 44.9, 44.8, 19.8; IR (Neat Film, 
NaCl) 3062, 3030, 2925, 2853, 1740, 1687, 1600, 1494, 1450, 1402, 1381, 1369, 1282, 
1233, 1155, 1074, 1028, 990, 950, 907, 793, 731 cm–1; HRMS (MM: ESI-APCI) m/z 
calc'd for C23H25N2O4 [M+H]+: 393.1809, found 393.1809. 
 
2-Chloroallyl 4-benzoyl-1-benzyl-3-oxopiperazine-2-carboxylate (10c) 
 
LiHMDS (100 mg, 0.61 mmol) was suspended in 2 mL of THF and cooled to –78 °C. 
Ketopiperazine (SI4, 150 mg, 0.51 mmol) dissolved in THF (2 mL) was then added 
dropwise and the solution allowed to stir at –78 °C for 30 minutes.  2-Chloroallyl 1H-
imidazole-1-carboxylate (130 mg, 0.66 mmol) dissolved in 1 mL of THF was then added 
dropwise.  The reaction mixture was allowed to stir for 8 hours at –78 °C and then 
warmed to 23 ºC and allowed to stir overnight.  The reaction mixture was then poured 
into 10 mL of water, extracted with EtOAc (4 x 15 mL), the combined organics washed 
with brine (1 x 15 mL), and dried with Na2SO4.  2-Chloroallyl 4-benzoyl-1-benzyl-3-
oxopiperazine-2-carboxylate (10c) was isolated as a yellow oil by flash column 
chromatography (SiO2, 10% EtOAc in hexanes to 15% EtOAc in hexanes).  46% yield.  
Rf = 0.5 (20% EtOAc in hexanes); 1H NMR (500 MHz, CDCl3) δ 7.68–7.61 (m, 2H), 
7.53–7.46 (m, 1H), 7.39 (dd, J = 7.8, 1.4 Hz, 2H), 7.38–7.35 (m, 4H), 7.32 (ttd, J = 8.7, 
4.3, 3.7, 2.4 Hz, 1H), 5.54 (dt, J = 2.1, 1.1 Hz, 1H), 5.46 (d, J = 1.9 Hz, 1H), 4.80 (s, 2H), 
4.21 (s, 1H), 3.94 (ddd, J = 12.5, 8.2, 4.3 Hz, 1H), 3.90–3.79 (m, 2H), 3.79–3.73 (m, 1H), 
3.33 (ddd, J = 12.3, 8.1, 3.9 Hz, 1H), 2.89–2.76 (m, 1H); 13C NMR (126 MHz, CDCl3) δ 
173.7, 167.3, 166.3, 136.3, 135.2, 135.0, 132.3, 129.1, 128.8, 128.4, 128.3, 128.1, 116.5, 
69.5, 67.2, 58.8, 44.9, 44.9; IR (Neat Film, NaCl) 3060, 3030, 2949, 2898, 2830, 1744, 
1689, 1599, 1491, 1448, 1381, 1280, 1232, 1178, 1138, 1074, 1026, 982, 906, 841, 795, 
BzN
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730 cm–1; HRMS (MM: ESI-APCI) m/z calc'd for C22H22ClN2O4 [M+H]+: 413.1263, 
found 413.1261. 
 
2-Phenylallyl 4-benzoyl-1-benzyl-3-oxopiperazine-2-carboxylate (10d) 
 
LiHMDS (140 mg, 0.83 mmol) was suspended in 3 mL of THF and cooled to –78 °C. 
Ketopiperazine (SI4, 200 mg, 0.69 mmol) dissolved in THF (3 mL) was then added 
dropwise to the LiHMDS solution and allowed to stir at –78 °C for 30 minutes.  2-
Phenylallyl 1H-imidazole-1-carboxylate (210 mg, 0.90 mmol) dissolved in 1 mL of THF 
was then added dropwise.  The reaction mixture was allowed to stir for 12 hours at –78 
°C and then warmed to 23 ºC and poured into 10 mL of water.  The aqueous layer was 
extracted with EtOAc (4 x 15 mL).  The combined organics were washed with brine (1 x 
15 mL), and dried with Na2SO4.  2-Phenylallyl 4-benzoyl-1-benzyl-3-oxopiperazine-2-
carboxylate (10d) was isolated as a yellow oil by flash column chromatography (SiO2, 
5% EtOAc in hexanes).  21% yield.  Rf = 0.4 (15% EtOAc in hexanes); 1H NMR (500 
MHz, CDCl3) δ 7.68–7.60 (m, 2H), 7.52–7.42 (m, 3H), 7.40–7.35 (m, 2H), 7.35–7.31 (m, 
3H), 7.31–7.26 (m, 3H), 7.24–7.17 (m, 2H), 5.64–5.57 (m, 1H), 5.46 (d, J = 0.9 Hz, 1H), 
5.24–5.10 (m, 2H), 4.13 (s, 1H), 3.87 (ddd, J = 12.7, 8.5, 4.4 Hz, 1H), 3.69–3.60 (m, 3H), 
3.13 (ddd, J = 12.5, 8.5, 3.9 Hz, 1H), 2.71 (dt, J = 12.2, 4.8 Hz, 1H); 13C NMR (126 
MHz, CDCl3) δ 173.7, 167.8, 166.5, 142.2, 137.9, 136.5, 135.3, 132.1, 129.0, 128.8, 
128.6, 128.4, 128.4, 128.3, 127.9, 126.3, 116.9, 69.5, 67.2, 58.4, 44.9, 44.5; IR (Neat 
Film, NaCl) 3061, 3027, 2925, 2849, 1738, 1688, 1600, 1495, 1450, 1402, 1369, 1281, 
1232, 1154, 1074, 1028, 977, 913, 780, 731 cm–1; HRMS (MM: ESI-APCI) m/z calc'd for 
C28H27N2O4 [M+H]+: 455.1965, found 455.1965. 
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Representative Procedure for the Asymmetric Decarboxylative Allylic 
Alkylation of 3-Oxopiperazine-2-carboxylates, 1,4-Diazepane-2-
carboxylates, 1-Oxooctahydro-9aH-pyrido[1,2-a]pyrazine-9a-
carboxylates, and 3-Oxo-1,4-diazaspiro[4.5]decane-2-carboxylates 
 
 
(S)-3-Allyl-1-benzoyl-4-benzyl-3-methylpiperazin-2-one (9b) 
 
In a nitrogen-filled glovebox, an oven-dried 20 mL scintillation vial was charged with 
[Pd2(pmdba)3] (27.4 mg, 0.025 mmol, 0.05 equiv) or [Pd2(dba)3] (22.9 mg, 0.025 mmol, 
0.05 equiv), (S)-(CF3)3-t-BuPHOX (37.0 mg, 0.063 mmol, 0.125 equiv), toluene (15 mL 
or 13 mL if the substrate is an oil), and a magnetic stir bar.  The vial was stirred at 
ambient glovebox temperature (~28 °C) for 30 min and then the substrate (8b, 182 mg, 
0.50 mmol) was added either as a solid or as a solution in toluene (2 mL).  The vial thus 
charged was sealed and heated to 40 °C.  When complete consumption of the starting 
material was observed by thin layer chromatography, the reaction mixture was removed 
from the glovebox, concentrated under reduced pressure, and purified by flash 
chromatography to afford the desired alkylated product.  Ketopiperazine 9b was isolated 
as a yellow oil by flash column chromatography (SiO2, 10% Et2O and 0.2% Me2NEt in 
hexanes).  89% yield.  Rf = 0.4 (10% EtOAc in hexanes, two developments); 1H NMR 
(500 MHz, CDCl3) δ 7.60–7.53 (m, 2H), 7.52–7.45 (m, 1H), 7.44–7.33 (m, 6H), 7.29 (t, J 
= 7.2 Hz, 1H), 6.06 (ddt, J = 17.1, 10.3, 7.2 Hz, 1H), 5.24–5.10 (m, 2H), 4.02 (d, J = 13.6 
Hz, 1H), 3.87 (d, J = 12.2 Hz, 1H), 3.60 (td, J = 11.9, 4.0 Hz, 1H), 3.43 (d, J = 13.3 Hz, 
BzN
NBn
O O
O
Me
8b
[Pd2(pmdba)3] (5 mol%)
(S)-(CF3)3-t-BuPHOX (12.5 mol %)
toluene
40 °C, 14 h
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1H), 2.98–2.74 (m, 3H), 2.64 (dd, J = 14.9, 6.5 Hz, 1H), 1.45 (s, 3H); 13C NMR (126 
MHz, CDCl3) δ 175.0, 174.3, 138.9, 136.3, 134.0, 131.6, 128.7, 128.2, 127.8, 127.5, 
118.1, 67.3, 53.0, 45.1, 42.2, 41.5, 18.7; IR (Neat Film, NaCl) 3063, 3029, 2974, 2827, 
1701, 1684, 1601, 1494, 1449, 1378, 1363, 1317, 1286, 1223, 1152, 1134, 1027, 993, 
912, 794, 724 cm–1; HRMS (MM: ESI-APCI) m/z calc'd for C22H25N2O2 [M+H]+: 
349.1911, found 349.1898; [α]D 25.0 –58.4 (c 0.97, MeOH, 91% ee). 
 
(S)-(2-Allyl-2-methyl-3-oxopiperazine-1,4-diyl)bis(phenylmethanone) (9a) 
 
Ketopiperazine 9a was isolated as an off-white foam by flash column chromatography 
(SiO2, 15% EtOAc in hexanes to 25% EtOAc in hexanes).  89% yield.  Rf = 0.4 (35% 
EtOAc in hexanes); 1H NMR (500 MHz, CDCl3) δ 7.59–7.54 (m, 2H), 7.54–7.50 (m, 
1H), 7.49–7.37 (m, 7H), 5.85 (dddd, J = 17.0, 10.1, 8.7, 6.2 Hz, 1H), 5.24 (ddt, J = 17.0, 
2.3, 1.2 Hz, 1H), 5.20 (dd, J = 10.1, 2.1 Hz, 1H), 4.14 (ddd, J = 13.1, 5.8, 2.9 Hz, 1H), 
3.79 (ddd, J = 13.1, 8.9, 2.9 Hz, 1H), 3.71 (ddd, J = 14.2, 5.8, 2.9 Hz, 1H), 3.60 (dd, J = 
13.9, 8.7 Hz, 1H), 3.53 (ddd, J = 14.2, 8.9, 2.9 Hz, 1H), 2.88 (ddt, J = 13.9, 6.2, 1.2 Hz, 
1H), 2.00 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 173.9, 172.5, 171.2, 137.0, 135.6, 
133.0, 131.9, 130.2, 128.9, 128.3, 127.6, 126.7, 119.9, 68.4, 46.6, 44.2, 39.4, 24.3; IR 
(Neat Film, NaCl) 3057, 2978, 2934, 1685, 1643, 1600, 1448, 1405, 1364, 1286, 1210, 
1149, 1075, 990, 934, 828, 788, 716 cm–1; HRMS (MM: ESI-APCI) m/z calc'd for 
C22H23N2O3 [M+H]+: 363.1703, found 363.1694; [α]D 25.0 –15.8 (c 0.78, MeOH, 52% ee). 
 
(S)-3-Allyl-1-benzoyl-4-(4-methoxybenzyl)-3-methylpiperazin-2-one (9c) 
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Ketopiperazine 9c was isolated as a yellow oil by flash column chromatography (SiO2, 
10% EtOAc in hexanes).  85% yield.  Rf = 0.4 (20% EtOAc in hexanes); 1H NMR (500 
MHz, CDCl3) δ 7.55 (dt, J = 8.4, 1.6 Hz, 2H), 7.51–7.43 (m, 1H), 7.42–7.34 (m, 2H), 
7.30 (d, J = 8.6 Hz, 2H), 6.93–6.85 (m, 2H), 6.05 (ddt, J = 17.1, 10.3, 6.9 Hz, 1H), 5.21–
5.10 (m, 2H), 3.94 (d, J = 13.4 Hz, 1H), 3.85 (dt, J = 12.3, 3.4 Hz, 1H), 3.82 (s, 3H), 3.55 
(ddd, J = 12.2, 10.7, 4.3 Hz, 1H), 3.34 (d, J = 13.4 Hz, 1H), 2.88 (dt, J = 12.7, 3.8 Hz, 
1H), 2.85–2.72 (m, 2H), 2.63 (dd, J = 14.9, 6.6 Hz, 1H), 1.43 (s, 3H); 13C NMR (126 
MHz, CDCl3) δ 175.2, 174.4, 159.0, 136.3, 134.1, 131.5, 130.8, 129.7, 128.2, 127.7, 
118.0, 114.0, 67.2, 55.4, 52.3, 45.2, 41.9, 41.4, 18.6; IR (Neat Film, NaCl) 2938, 2834, 
1683, 1611, 1512, 1449, 1377, 1317, 1287, 1245, 1224, 1177, 1153, 1133, 1034, 910, 822 
cm–1; HRMS (MM: ESI-APCI) m/z calc'd for C23H27N2O3 [M+H]+: 379.2016, found 
379.1999; [α]D 25.0 –75.0 (c 0.86, CHCl3, 90% ee). 
 
 (S)-3-Allyl-4-benzyl-1-(4-fluorobenzoyl)-3-methylpiperazin-2-one (9d) 
 
Ketopiperazine 9d was isolated as a yellow oil by flash column chromatography (SiO2, 
5% EtOAc in hexanes to 10% EtOAc in hexanes).  86% yield.  Rf = 0.5 (15% EtOAc in 
hexanes); 1H NMR (500 MHz, CDCl3) δ 7.59 (dd, J = 8.1, 5.7 Hz, 2H), 7.40 (d, J = 7.5 
Hz, 2H), 7.35 (t, J = 7.4 Hz, 2H), 7.29 (t, J = 7.0 Hz, 1H), 7.06 (t, J = 8.5 Hz, 2H), 6.08 
(ddt, J = 17.2, 9.9, 6.9 Hz, 1H), 5.17 (t, J = 13.8 Hz, 2H), 4.02 (d, J = 13.7 Hz, 1H), 3.85 
(dt, J = 12.1, 3.1 Hz, 1H), 3.57 (td, J = 11.4, 4.2 Hz, 1H), 3.41 (d, J = 13.7 Hz, 1H), 2.89 
(dt, J = 12.7, 3.6 Hz, 1H), 2.80 (tt, J = 11.0, 5.1 Hz, 2H), 2.72–2.58 (m, 1H), 1.44 (s, 3H); 
13C NMR (126 MHz, CDCl3) δ 175.2, 173.2, 164.8 (d, 1JCF = 252.5 Hz), 138.9, 134.0, 
132.3 (d, 4JCF = 3.3 Hz), 130.5 (d, 3JCF = 9.0 Hz), 128.7, 128.6, 127.5, 118.1, 115.3 (d, 
2JCF = 22.1 Hz), 67.3, 53.0, 45.3, 42.2, 41.5, 18.7; IR (Neat Film, NaCl) 3065, 3027, 
2976, 2942, 2828, 1681, 1602, 1507, 1453, 1408, 1378, 1318, 1285, 1226, 1152, 1134, 
1098, 1028, 994, 913, 843, 769, 738 cm–1; HRMS (MM: ESI-APCI) m/z calc'd for 
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C22H24FN2O2 [M+H]+: 367.1816, found 367.1799; [α]D 25.0 –58.1 (c 1.00, CHCl3, 94% 
ee). 
 
(S)-3-Allyl-4-benzyl-1-(4-methoxybenzoyl)-3-methylpiperazin-2-one (9e) 
 
Ketopiperazine 9e was isolated as a colorless oil by flash column chromatography (SiO2, 
20% EtOAc in hexanes).  87% yield.  Rf = 0.4 (35% EtOAc in hexanes); 1H NMR (500 
MHz, CDCl3) δ 7.65–7.55 (m, 2H), 7.44–7.26 (m, 5H), 6.93–6.83 (m, 2H), 6.08 (ddt, J = 
17.1, 10.4, 7.1 Hz, 1H), 5.23–5.10 (m, 2H), 4.02 (d, J = 13.7 Hz, 1H), 3.85 (s, 3H), 3.80 
(dt, J = 12.1, 3.4 Hz, 1H), 3.57 (ddd, J = 12.1, 10.5, 4.3 Hz, 1H), 3.41 (d, J = 13.7 Hz, 
1H), 2.95–2.73 (m, 3H), 2.63 (dd, J = 14.9, 6.5 Hz, 1H), 1.45 (s, 3H); 13C NMR (126 
MHz, CDCl3) δ 174.9, 173.9, 162.8, 139.0, 134.3, 130.7, 128.6, 128.6, 128.0, 127.4, 
117.9, 113.5, 67.1, 55.5, 53.0, 45.3, 42.3, 41.4, 18.7; IR (Neat Film, NaCl) 3066, 2974, 
2838, 1676, 1604, 1579, 1511, 1495, 1452, 1419, 1378, 1363, 1317, 1284, 1224, 1170, 
1153, 1134, 1027, 993, 913, 838, 801, 770, 738 cm–1; HRMS (MM: ESI-APCI) m/z 
calc'd for C23H27N2O3 [M+H]+: 379.2016, found 379.1991; [α]D 25.0 –36.5 (c 0.70, CHCl3, 
93% ee). 
 
(S)-3-Allyl-4-benzyl-1-(2-fluorobenzoyl)-3-methylpiperazin-2-one (9f) 
 
Ketopiperazine 9f was isolated as a yellow oil by flash column chromatography (SiO2, 
10% EtOAc in hexanes to 20% EtOAc in hexanes).  86% yield.  Rf = 0.4 (20% EtOAc in 
hexanes); 1H NMR (500 MHz, CDCl3) δ 7.68–7.59 (m, 1H), 7.50–7.45 (m, 1H), 7.45–
7.41 (m, 1H), 7.41–7.37 (m, 2H), 7.38–7.32 (m, 1H), 7.31–7.26 (m, 1H), 7.21 (td, J = 
7.5, 1.0 Hz, 1H), 7.05 (ddd, J = 10.2, 8.3, 0.9 Hz, 1H), 5.96 (ddt, J = 17.1, 10.3, 7.0 Hz, 
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1H), 5.11 (ddt, J = 10.3, 2.1, 1.1 Hz, 1H), 5.07 (dq, J = 17.1, 1.4 Hz, 1H), 3.99 (d, J = 
13.7 Hz, 1H), 3.88 (dt, J = 12.5, 3.5 Hz, 1H), 3.60 (ddd, J = 12.5, 10.5, 4.4 Hz, 1H), 3.41 
(d, J = 13.7 Hz, 1H), 2.91–2.83 (m, 1H), 2.83–2.75 (m, 2H), 2.59 (dd, J = 14.8, 7.2 Hz, 
1H), 1.42 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 174.6, 169.0, 158.5 (d, 1JCF  = 249.6), 
143.3, 138.9, 133.9, 132.0 (d, 4JCF  = 8.4), 129.1 (d, 6JCF  = 2.8), 128.5, 127.3, 126.1 (d, 
3JCF  = 14.9), 124.2 (d, 5JCF  = 3.4), 117.7, 115.3 (d, 2JCF  = 21.6), 67.2, 52.8, 44.9, 41.9, 
41.5, 18.5; IR (Neat Film, NaCl) 3064, 2828, 1701, 1680, 1616, 1493, 1452, 1399, 1377, 
1363, 1261, 1158, 1135, 1103, 1028, 992, 914, 857, 820, 756, 740 cm–1; HRMS (MM: 
ESI-APCI) m/z calc'd for C22H24FN2O2 [M+H]+: 367.1816, found 367.1824; [α]D 25.0 –
80.9 (c 1.00, CHCl3, 87% ee). 
 
Benzyl (S)-3-allyl-4-benzyl-3-methyl-2-oxopiperazine-1-carboxylate (9g) 
 
Ketopiperazine 9g was isolated as a colorless oil by flash column chromatography (SiO2, 
10% EtOAc in hexanes to 20% EtOAc in hexanes).  86% yield.  Rf = 0.5 (20% EtOAc in 
hexanes); 1H NMR (500 MHz, CDCl3) δ 7.46–7.26 (m, 10H), 5.96 (ddt, J = 17.3, 10.2, 
7.1 Hz, 1H), 5.36–5.19 (m, 2H), 5.16–5.00 (m, 2H), 3.96 (d, J = 13.7 Hz, 1H), 3.63 (dt, J 
= 11.8, 3.3 Hz, 1H), 3.51 (ddd, J = 11.8, 10.3, 5.0 Hz, 1H), 3.32 (d, J = 13.7 Hz, 1H), 
2.85–2.73 (m, 1H), 2.73–2.51 (m, 3H), 1.41 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 
173.7, 153.6, 138.9, 135.4, 133.6, 128.5, 128.4, 128.2, 128.0, 127.2, 117.8, 68.4, 68.4, 
52.7, 46.7, 42.6, 41.6, 18.2; IR (Neat Film, NaCl) 3063, 3029, 2976, 2827, 1775, 1713, 
1454, 1377, 1317, 1282, 1221, 1025, 992 cm–1; HRMS (MM: ESI-APCI) m/z calc'd for 
C22H27N2O3 [M+H]+: 379.2016, found 379.2016; [α]D 25.0 –36.0 (c 1.00, CHCl3, 81% ee). 
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 (S)-3-Allyl-1-benzoyl-4-benzyl-3-ethylpiperazin-2-one (9h) 
 
Ketopiperazine 9h was isolated as a colorless oil by flash column chromatography (SiO2, 
10% EtOAc in hexanes to 20% EtOAc in hexanes).  85% yield.  Rf = 0.5 (20% EtOAc in 
hexanes); 1H NMR (500 MHz, CDCl3) δ 7.60–7.53 (m, 2H), 7.53–7.45 (m, 1H), 7.37 
(ddd, J = 21.1, 8.5, 7.0 Hz, 6H), 7.32–7.26 (m, 1H), 5.99 (ddt, J = 17.3, 10.1, 7.2 Hz, 
1H), 5.24–5.08 (m, 2H), 3.92 (d, J = 13.9 Hz, 1H), 3.79 (d, J = 13.9 Hz, 1H), 3.76–3.65 
(m, 2H), 3.05 (ddd, J = 12.3, 7.9, 4.3 Hz, 1H), 2.94 (dt, J = 12.7, 4.5 Hz, 1H), 2.77–2.62 
(m, 2H), 2.03 (dq, J = 14.7, 7.4 Hz, 1H), 1.85 (dq, J = 14.6, 7.3 Hz, 1H), 1.03 (t, J = 7.4 
Hz, 3H); 13C NMR (126 MHz, CDCl3) δ174.8, 173.5, 139.1, 136.6, 134.6, 131.6, 128.7, 
128.4, 128.2, 127.8, 127.4, 118.2, 70.2, 52.7, 45.4, 42.6, 40.1, 28.7, 9.7; IR (Neat Film, 
NaCl) 3062, 3028, 2976, 2837, 1682, 1601, 1583, 1495, 1450, 1401, 1376, 1284, 1221, 
1152, 1069, 1027, 1002, 967, 915, 879, 793, 722 cm–1; HRMS (MM: ESI-APCI) m/z 
calc'd for C23H27N2O2 [M+H]+: 363.2067, found 363.2078; [α]D 25.0 +26.7 (c 1.00, CHCl3, 
97% ee). 
 
 (S)-3-Allyl-1-benzoyl-4-benzyl-3-isobutylpiperazin-2-one (9i) 
 
Ketopiperazine 9i was isolated by flash column chromatography (SiO2, 8% Et2O in 
hexanes to 10% Et2O in hexanes) as a yellow oil.  69% yield.  Rf = 0.6 (20% E2O in 
hexanes); 1H NMR (500 MHz, CDCl3) δ 7.56 (m, 2H), 7.52–7.44 (m, 1H), 7.38 (m, 6H), 
7.33–7.27 (m, 1H), 5.95 (ddt, J = 17.1, 10.1, 7.3 Hz, 1H), 5.26–5.11 (m, 2H), 4.00 (d, J = 
14.0 Hz, 1H), 3.83–3.73 (m, 2H), 3.71 (d, J = 14.0 Hz, 1H), 3.09 (ddd, J = 13.4, 9.9, 3.8 
Hz, 1H), 2.92 (dt, J = 12.7, 3.8 Hz, 1H), 2.79 (dd, J = 14.2, 7.0 Hz, 1H), 2.63 (dd, J = 
14.1, 7.6 Hz, 1H), 2.09–1.91 (m, 2H), 1.80–1.67 (m, 1H), 0.89 (d, J = 2.9 Hz, 3H), 0.88 
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(d, J = 2.9 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 175.0, 173.0, 138.8, 136.6, 134.4, 
131.6, 128.8, 128.1, 128.1, 127.9, 127.4, 118.2, 68.6, 53.0, 45.5, 43.9, 42.4, 40.0, 24.7, 
24.4, 22.5; IR (Neat Film, NaCl) 3062, 3027, 2955, 2868, 1682, 1600, 1495, 1468, 1450, 
1399, 1365, 1315, 1284, 1220, 1153, 1113, 1024, 984, 917, 843, 794, 724 cm–1; HRMS 
(MM: ESI-APCI) m/z calc'd for C25H31N2O2 [M+H]+: 391.2380, found 391.2388; [α]D 25.0 
+24.6 (c 1.00, CHCl3, 85% ee). 
 
(R)-3-Allyl-1-benzoyl-3,4-dibenzylpiperazin-2-one (9j) 
 
Ketopiperazine 9j was isolated by flash column chromatography (SiO2, hexanes to 10% 
EtOAc in hexanes) as a colorless oil.  99% yield.  Rf = 0.6 (20% EtOAc in hexanes); 1H 
NMR (500 MHz, CDCl3) δ 7.48 (dd, J = 7.6, 2.6 Hz, 2H), 7.44–7.34 (m, 2H), 7.34–7.14 
(m, 11H), 6.06 (ddt, J = 17.3, 10.2, 7.2 Hz, 1H), 5.40–5.06 (m, 2H), 4.14 (d, J = 13.9 Hz, 
1H), 3.92 (d, J = 13.9 Hz, 1H), 3.60 (ddd, J = 12.2, 6.0, 3.7 Hz, 1H), 3.49–3.33 (m, 2H), 
3.06 (d, J = 14.3 Hz, 1H), 2.97–2.80 (m, 3H), 2.74 (ddd, J = 12.7, 6.0, 3.7 Hz, 1H); 13C 
NMR (126 MHz, CDCl3) δ 174.4, 173.1, 137.7, 136.5, 134.2, 131.6, 130.8, 128.6, 128.5, 
128.3, 128.1, 127.9, 127.4, 126.8, 118.8, 71.5, 52.8, 45.2, 42.5, 42.1, 41.6; IR (Neat Film, 
NaCl) 3062, 3029, 2929, 2848, 1683, 1622, 1495, 1450, 1339, 1283, 1223, 1153, 1096, 
1028, 993, 918 cm–1; HRMS (MM: ESI-APCI) m/z calc'd for C28H29N2O2 [M+H]+: 
425.2224, found 425.2224; [α]D 25.0 +31.8 (c 1.00, CHCl3, 97% ee). 
 
(R)-3-Allyl-1-benzoyl-4-benzyl-3-[(benzyloxy)methyl]piperazin-2-one (9k) 
 
Ketopiperazine 9k was isolated by flash column chromatography (SiO2, 5% EtOAc in 
hexanes to 10% EtOAc in hexanes) as a colorless oil.  56% yield.  Rf = 0.7 (15% EtOAc 
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in hexanes); 1H NMR (500 MHz, CDCl3) δ 7.68–7.60 (m, 2H), 7.49–7.43 (m, 1H), 7.43–
7.26 (m, 12H), 6.00 (ddt, J = 17.2, 10.2, 7.0 Hz, 1H), 5.19–5.14 (m, 1H), 5.12 (dd, J = 
17.1, 1.7 Hz, 1H), 4.64 (d, J = 11.9 Hz, 1H), 4.56 (d, J = 11.9 Hz, 1H), 4.06 (d, J = 13.6 
Hz, 1H), 3.94–3.85 (m, 2H), 3.82 (dt, J = 12.2, 3.1 Hz, 1H), 3.70–3.58 (m, 2H), 3.41 (td, 
J = 11.6, 3.1 Hz, 1H), 2.85 (dt, J = 12.0, 3.4 Hz, 1H), 2.54 (dd, J = 14.4, 7.4 Hz, 1H), 
2.43 (dd, J = 14.4, 6.5 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 174.4, 173.3, 139.2, 
137.9, 136.1, 133.4, 131.6, 128.7, 128.6, 128.6, 128.3, 128.0, 127.8, 127.3, 118.6, 75.8, 
73.9, 70.3, 52.9, 45.2, 43.9, 37.9; IR (Neat Film, NaCl) 3063, 3029, 2953, 2923, 2862, 
1686, 1601, 1495, 1451, 1403, 1373, 1326, 1284, 1246, 1224, 1154, 1111, 1028, 985, 
915, 848, 794, 748 cm–1; HRMS (MM: ESI-APCI) m/z calc'd for C29H31N2O3 [M+H]+: 
455.2329, found 455.2325; [α]D 25.0 –20.3 (c 1.00, CHCl3, 95% ee). 
 
 (S)-1-Benzoyl-4-benzyl-3-methyl-3-(2-phenylallyl)piperazin-2-one (9l) 
 
Ketopiperazine 9l was isolated by flash column chromatography (SiO2, 5% acetone in 
hexanes) as a colorless oil.  77% yield.  R= 0.4 (15% acetone in hexanes) 1H NMR (500 
MHz, CDCl3) δ7.44 (dd, J = 18.2, 7.6 Hz, 3H), 7.39 – 7.19 (m, 12H), 5.38 (s, 1H), 5.29 
(s, 1H), 4.04 (d, J = 13.3 Hz, 1H), 3.61 (d, J = 12.3 Hz, 1H), 3.44 (d, J = 15.6 Hz, 1H), 
3.34 (d, J = 13.1 Hz, 1H), 3.29 (d, J = 3.6 Hz, 1H), 2.94 (d, J = 15.6 Hz, 1H), 2.80 (d, J = 
12.6 Hz, 1H), 2.74 – 2.62 (m, 1H), 1.47 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 174.2, 
173.9, 146.1, 142.2, 138.7, 136.6, 131.3, 128.8, 128.5, 128.1, 128.0, 127.7, 127.5, 127.4, 
127.3, 117.3, 67.2, 53.4, 44.9, 42.7, 42.2, 19.6; IR (Neat Film, NaCl) 3059, 3027, 2933, 
2829, 1682, 1600, 1494, 1449, 1379, 1363, 1317, 1287, 1223, 1146, 1133, 1074, 1028, 
967, 945, 908, 850, 794, 778, 726 cm–1; HRMS (MM: ESI-APCI) m/z calc'd for 
C28H29N2O2 [M+H]+: 425.2224, found 425.2214; [α]D 25.0 -73.3 (c 1.00, CHCl3, 96% ee). 
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(S)-1-Benzoyl-4-benzyl-3-(2-chloroallyl)-3-methylpiperazin-2-one (9m) 
 
Ketopiperazine 9m was isolated by flash column chromatography (SiO2, 5% EtOAc in 
hexanes) as a colorless oil.  60% yield. Rf = 0.4 (20% EtOAc in hexanes) 1H NMR (500 
MHz, CDCl3) δ 7.60 – 7.53 (m, 2H), 7.53 – 7.45 (m, 1H), 7.40 (td, J = 6.8, 1.3 Hz, 4H), 
7.34 (td, J = 6.7, 6.2, 1.6 Hz, 2H), 7.31 – 7.27 (m, 1H), 5.27 (t, J = 1.1 Hz, 1H), 5.24 (t, J 
= 1.3 Hz, 1H), 4.02 (d, J = 13.5 Hz, 1H), 3.80 (dt, J = 12.3, 3.1 Hz, 1H), 3.73 (ddd, J = 
12.3, 11.1, 4.0 Hz, 1H), 3.44 (dt, J = 15.7, 1.2 Hz, 1H), 3.38 (d, J = 13.5 Hz, 1H), 2.87 
(dt, J = 12.7, 3.8 Hz, 1H), 2.81 (ddd, J = 14.2, 9.9, 2.6 Hz, 2H), 1.49 (s, 3H); 13C NMR 
(126 MHz, CDCl3) δ 174.3, 174.0, 139.0, 138.5, 136.5, 131.6, 128.7, 128.6, 128.2, 127.9, 
127.5, 115.9, 66.0, 53.5, 45.8, 45.0, 42.5, 18.9; IR (Neat Film, NaCl) 3062, 3029, 2938, 
2849, 1682, 1633, 1600, 1495, 1449, 1399, 1378, 1364, 1322, 1287, 1243, 1224, 1210, 
1178, 1157, 1135, 1080, 1062, 1030, 997, 968, 944, 879, 850, 794, 725 cm–1; HRMS 
(MM: ESI-APCI) m/z calc'd for C22H24N2O2Cl [M+H]+: 383.1521, found 383.1523. [α]D 
25.0 -97.0 (c 1.00, CHCl3, 98% ee). 
 
(S)-9a-Allyl-2-benzoylhexahydro-2H-pyrido[1,2-a]pyrazin-1(6H)-one (9n) 
 
Bicyclic ketopiperazine 9n was isolated by flash column chromatography (SiO2, 15% 
EtOAc and 1% NEt3 in hexanes) as a colorless oil.  68% yield.  Rf = 0.4 (25% EtOAc in 
hexanes); 1H NMR (500 MHz, CDCl3) δ 7.56–7.49 (m, 2H), 7.50–7.43 (m, 1H), 7.41–
7.34 (m, 2H), 5.82 (ddt, J = 16.9, 10.1, 7.6, Hz, 1H), 5.25–5.10 (m, 2H), 4.09 (ddd, J = 
12.7, 9.7, 5.2 Hz, 1H), 3.72 (dt, J = 12.7, 4.5 Hz, 1H), 3.39 (ddd, J = 13.8, 9.9, 4.8 Hz, 
1H), 3.04 (dt, J = 13.3, 4.6 Hz, 1H), 3.00–2.90 (m, 1H), 2.75 (ddt, J = 21.0, 14.5, 6.9 Hz, 
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3H), 1.87 (td, J = 11.0, 8.9, 3.5 Hz, 1H), 1.76–1.62 (m, 2H), 1.62–1.45 (m, 3H); 13C 
NMR (126 MHz, CDCl3) δ 175.3, 174.7, 136.3, 132.8, 131.4, 128.1, 127.5, 118.2, 64.4, 
49.4, 44.8, 44.1, 35.9, 29.4, 23.6, 20.4; IR (Neat Film, NaCl) 3071, 2935, 2860, 1681, 
1600, 1466, 1448, 1379, 1359, 1315, 1282, 1233, 1206, 1153, 1110, 1036, 997, 918, 795, 
724 cm–1; HRMS (MM: ESI-APCI) m/z calc'd for C18H23N2O2 [M+H]+: 299.1754, found 
299.1744; [α]D 25.0 +20.9 (c 0.85, CHCl3, 90% ee). 
 
(S)-3-Allyl-1-benzoyl-4-benzyl-3-methyl-1,4-diazepan-2-one (9o) 
 
Ketopiperazine 9o was isolated by flash column chromatography (SiO2, 5% EtOAc in 
hexanes to 10% EtOAc in hexanes) as a yellow oil.  89% yield.  Rf = 0.4 (10% EtOAc in 
hexanes); 1H NMR (500 MHz, CDCl3) δ 7.64–7.53 (m, 2H), 7.53–7.44 (m, 1H), 7.44–
7.31 (m, 6H), 7.31–7.27 (m, 1H), 6.10–5.92 (m, 1H), 5.28–5.15 (m, 2H), 4.30 (ddd, J = 
12.0, 8.0, 3.4 Hz, 1H), 4.11 (ddd, J = 14.1, 6.5, 3.8 Hz, 1H), 3.98 (d, J = 13.8 Hz, 1H), 
3.85 (d, J = 13.8 Hz, 1H), 2.96 (m, 2H), 2.80 (dd, J = 14.7, 7.0 Hz, 1H), 2.69 (dd, J = 
14.7, 7.4 Hz, 1H), 1.81–1.62 (m, 2H), 1.53 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 179.5, 
175.6, 140.0, 137.0, 133.8, 131.3, 128.5, 128.5, 128.3, 127.7, 127.3, 118.8, 69.8, 52.4, 
45.6, 42.7, 42.4, 26.5, 22.0; IR (Neat Film, NaCl) 3063, 3028, 2976, 2941, 2850, 2252, 
1682, 1600, 1583, 1494, 1450, 1376, 1353, 1279, 1228, 1210, 1175, 1076, 1023, 966, 
918, 872, 848, 790, 737 cm–1; HRMS (MM: ESI-APCI) m/z calc'd for C23H27N2O2 
[M+H]+: 363.2067, found 363.2066; [α]D 25.0 +2.0 (c 1.00, CHCl3, 59% ee). 
 
(S)-3-Allyl-1-benzoyl-3-methyl-4-phenylpiperazin-2-one (9p) 
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Ketopiperazine 9p was isolated by flash column chromatography (SiO2, 5% EtOAc in 
hexanes to 10% EtOAc in hexanes) as a colorless oil.  83% yield.  Rf = 0.6 (15% EtOAc 
in hexanes); 1H NMR (500 MHz, CDCl3) δ 7.64–7.55 (m, 2H), 7.48 (tt, J = 6.9, 1.3 Hz, 
1H), 7.44–7.36 (m, 2H), 7.33 (td, J = 7.4, 1.9 Hz, 2H), 7.24–7.12 (m, 3H), 6.24–6.10 (m, 
1H), 5.26–5.20 (m, 1H), 5.17 (dq, J = 17.2, 1.6 Hz, 1H), 4.11 (ddd, J = 12.3, 4.6, 3.5 Hz, 
1H), 3.85 (ddd, J = 12.4, 9.3, 3.9 Hz, 1H), 3.71–3.55 (m, 1H), 3.47 (dt, J = 12.7, 4.2 Hz, 
1H), 2.63 (dd, J = 15.2, 7.6 Hz, 1H), 2.56 (ddt, J = 15.2, 5.6, 1.6 Hz, 1H), 1.31 (s, 3H); 
13C NMR (126 MHz, CDCl3) δ 175.2, 174.0, 147.9, 136.3, 134.0, 131.6, 128.8, 128.1, 
127.8, 126.8, 125.2, 118.6, 68.1, 46.2, 45.3, 42.9, 21.8; IR (Neat Film, NaCl) 3062, 3032, 
2975, 2933, 2844, 1683, 1597, 1492, 1449, 1373, 1323, 1284, 1229, 1177, 1128, 1026, 
1002, 961, 918, 835, 792, 773, 723 cm–1; HRMS (MM: ESI-APCI) m/z calc'd for 
C21H23N2O2 [M+H]+: 335.1754, found 335.1757; [α]D 25.0 +25.2 (c 1.00, CHCl3, 94% ee). 
 
(S)-3-Allyl-1-benzoyl-3,4-dimethylpiperazin-2-one (9q) 
 
Ketopiperazine 9q was isolated by flash column chromatography (SiO2, 5% acetone in 
hexanes) as a colorless oil.  88% yield.  Rf = 0.5 (10% acetone in hexanes); 1H NMR (500 
MHz, CDCl3) δ 7.53 (dd, J = 8.3, 1.3 Hz, 2H), 7.50–7.43 (m, 1H), 7.42–7.33 (m, 2H), 
5.95–5.79 (m, 1H), 5.14–5.10 (m, 1H), 5.10–5.05 (m, 1H), 3.90 (dt, J = 12.3, 3.6 Hz, 
1H), 3.73 (ddd, J = 12.3, 10.4, 4.7 Hz, 1H), 3.04 (ddd, J = 14.2, 10.4, 3.9 Hz, 1H), 2.95 
(dt, J = 12.8, 4.1 Hz, 1H), 2.73 (dd, J = 14.8, 7.2 Hz, 1H), 2.41 (app s, 4H), 1.32 (s, 3H); 
13C NMR (126 MHz, CDCl3) δ 175.1, 174.5, 136.3, 134.0, 131.6, 128.2, 127.7, 117.7, 
66.6, 46.7, 44.7, 40.9, 37.4, 17.3; IR (Neat Film, NaCl) 3072, 2977, 2948, 2849, 2809, 
1685, 1600, 1450, 1368, 1318, 1286, 1261, 1217, 1153, 1085, 949, 911, 845, 794, 752, 
724 cm–1; HRMS (MM: ESI-APCI) m/z calc'd for C16H21N2O2 [M+H]+: 273.1598, found 
273.1598; [α]D 25.0 –66.6 (c 1.00, CHCl3, 82% ee). 
 
 
 
BzN
NMe
Me
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(S)-3-Allyl-1-benzoyl-4-benzylpiperazin-2-one (11a) 
 
Ketopiperazine 11a was isolated by flash column chromatography (SiO2, 5% EtOAc in 
hexanes to 10% EtOAc in hexanes) as a colorless oil.  89% yield.  Rf = 0.6 (20% EtOAc 
in hexanes); 1H NMR (500 MHz, CDCl3) δ 7.61–7.54 (m, 2H), 7.53–7.45 (m, 1H), 7.43–
7.34 (m, 6H), 7.34–7.28 (m, 1H), 6.12–5.91 (m, 1H), 5.26–5.16 (m, 2H), 4.08 (d, J = 
13.3 Hz, 1H), 4.02 (ddd, J = 12.7, 4.6, 3.7 Hz, 1H), 3.62 (ddd, J = 12.7, 9.6, 4.0 Hz, 1H), 
3.43 (d, J = 13.3 Hz, 1H), 3.39–3.32 (m, 1H), 3.14 (dt, J = 12.7, 4.2 Hz, 1H), 2.92–2.80 
(m, 1H), 2.80–2.71 (m, 1H), 2.57 (ddd, J = 13.0, 9.6, 3.6 Hz, 1H); 13C NMR (126 MHz, 
CDCl3) δ 173.9, 172.2, 137.5, 136.0, 134.1, 131.7, 129.0, 128.7, 128.1, 128.0, 127.7, 
118.0, 66.8, 58.3, 46.4, 44.0, 34.6; IR (Neat Film, NaCl) 3062, 3028, 2947, 2899, 2811, 
1683, 1450, 1283, 1229, 1140, 1072, 1028, 993, 917, 794 cm–1; HRMS (MM: ESI-APCI) 
m/z calc'd for C21H23N2O2 [M+H]+: 335.1754, found 335.1758; [α]D 25.0 –20.8 (c 1.00, 
CHCl3, 98% ee). 
 
(S)-1-Benzoyl-4-benzyl-3-(2-methylallyl)piperazin-2-one (11b) 
 
Ketopiperazine 11b was isolated as an yellow oil by flash column chromatography (SiO2, 
5% EtOAc in hexanes).  74% yield.  Rf = 0.4 (20% EtOAc in hexanes); 1H NMR (500 
MHz, CDCl3) δ 7.56–7.55 (m, 2H), 7.49 (tt, J = 6.9, 1.3, 1H), 7.43–7.37 (m, 2H), 7.35 (d, 
J = 4.8, 4H), 7.32–7.27 (m, 1H), 4.91 (d, J = 15.8, 2H), 4.15–3.89 (m, 2H), 3.76–3.59 (m, 
1H), 3.59–3.48 (m, 1H), 3.49–3.36 (m, 1H), 3.33–3.10 (m, 1H), 2.95–2.75 (m, 1H), 2.67 
(tq, J = 16.0, 8.9, 2H), 1.74 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 174.1, 172.8, 136.0, 
131.8, 129.4, 129.1, 129.1, 128.7, 128.2, 128.1, 114.0, 110.1, 65.0, 58.4, 45.3, 38.6, 31.1, 
22.6; IR (Neat Film, NaCl) 3067, 3027, 2923, 2852, 1685, 1597, 1512, 1449, 1364, 1318, 
1283, 1156, 1133, 1073, 1027, 945, 895, 795, 728 cm–1; HRMS (MM: ESI-APCI) m/z 
BzN
NBn
O
BzN
NBn
O
Me
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calc'd for C22H25N2O2 [M+H]+: 349.1911, found 349.1914; [α]D 25.0 –18.3 (c 0.27, CHCl3, 
97% ee). 
 
(S)-1-Benzoyl-4-benzyl-3-(2-chloroallyl)piperazin-2-one (11c) 
 
Ketopiperazine 11c was isolated as an yellow oil by flash column chromatography (SiO2, 
5% acetone in hexanes).  52% yield.  Rf = 0.6 (15% EtOAc in hexanes); 1H NMR (500 
MHz, CDCl3) δ 7.59–7.53 (m, 2H), 7.53–7.46 (m, 1H), 7.44–7.27 (m, 7H), 5.38–5.30 (m, 
2H), 4.18–4.04 (m, 1H), 4.04–3.93 (m, 1H), 3.80–3.67 (m, 1H), 3.65–3.45 (m, 2H), 3.16 
(ddd, J = 27.2, 8.8, 3.8, 2H), 3.01 (dd, J = 15.2, 5.4, 1H), 2.65 (ddd, J = 12.7, 8.8, 3.6, 
1H); 13C NMR (126 MHz, CDCl3) δ 173.6, 171.5, 138.8, 135.8, 131.9, 129.1, 128.8, 
128.3, 128.1, 127.9, 115.8, 110.1, 64.4, 58.5, 45.8, 43.3, 40.0; IR (Neat Film, NaCl) 
3062, 3030, 2953, 2816, 1682, 1634, 1601, 1450, 1383, 1366, 1283, 1227, 1162, 1140, 
1073, 1022, 910, 795, 746 cm–1; HRMS (MM: ESI-APCI) m/z calc'd for C21H22N2O2 
[M+H]+: 369.1364, found 369.1371; [α]D 25.0 –28.9 (c 0.36, CHCl3, 87% ee). 
 
(S)-1-Benzoyl-4-benzyl-3-(2-phenylallyl)piperazin-2-one (11d) 
 
Ketopiperazine 11d was isolated as an yellow oil by flash column chromatography (SiO2, 
10% EtOAc in hexanes).  72% yield.  Rf = 0.5 (20% EtOAc in hexanes); 1H NMR (500 
MHz, CDCl3) δ 7.55–7.50 (m, 2H), 7.49 (dt, J = 7.0, 1.5, 1H), 7.44–7.36 (m, 4H), 7.29 
(dtd, J = 12.5, 6.7, 2.8, 6H), 7.25–7.19 (m, 2H), 5.35 (d, J = 25.9, 2H), 3.93 (ddd,  J = 
12.9, 7.3, 4.5, 2H), 3.53 (ddd, J = 12.3, 7.6, 3.8, 1H), 3.43 (dd, J = 12.1, 4.1, 2H), 3.23 
(qd, J = 14.9, 5.8, 2H), 3.12 (ddd, J = 13.0, 6.4, 3.9, 1H), 2.58 (ddd, J = 12.4, 7.7, 3.8, 
1H); 13C NMR (126 MHz, CDCl3) δ 173.6, 172.7, 145.5, 140.4, 137.6, 135.9, 131.6, 
128.8, 128.4, 128.4, 128.1, 127.9, 127.6, 127.4, 126.7, 116.0, 65.3, 58.3, 44.6, 43.1, 37.5; 
BzN
NBn
O
Cl
BzN
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IR (Neat Film, NaCl) 3059, 3029, 2924, 2852, 1682, 1600, 1494, 1449, 1364, 1283, 
1222, 1156, 1073, 1028, 903, 780, 732 cm–1; HRMS (MM: ESI-APCI) m/z calc'd for 
C27H27N2O2 [M+H]+: 411.2067, found 411.2070; [α]D 25.0 –7.3 (c 1.00, CHCl3, 99% ee). 
 
Procedures for Preparation of α-Quaternary Piperazines 
 
 
(S)-3-Allyl-4-benzyl-3-methylpiperazin-2-one (12) 
 
Ketopiperazine 9b (56.0 mg, 0.16 mmol) was taken up in MeOH (4 mL) and H2O (4 mL) 
and stirred with lithium hydroxide monohydrate (10.0 mg, 0.24 mmol) for 16 hours open 
to air.  Reaction mixture was then diluted with EtOAc and washed once with saturated 
aqueous sodium bicarbonate.  The aqueous layer was extracted with EtOAc (3 x 20 mL) 
and the organic layers were combined, washed once with brine, dried with Na2SO4, and 
concentrated under reduced pressure to give 12 as a white solid.  76% yield.  Rf = 0.3 
(50% EtOAc in hexanes); 1H NMR (500 MHz, CDCl3) δ 7.31 (d, J = 7.5, 2H), 7.24 (td, J 
= 6.7, 6.2, 1.6, 2H), 7.21–7.13 (m, 1H), 6.13 (s, 1H), 5.99–5.86 (m, 1H), 5.09–4.99 (m, 
2H), 3.92 (d, J=13.7, 1H), 3.26 (d, J = 13.8, 1H), 3.24–3.18 (m, 1H), 2.99 (dq, J = 11.0, 
3.3, 1H), 2.83–2.70 (m, 1H), 2.67–2.52 (m, 2H), 2.48 (dd, J = 14.6, 7.3, 1H), 1.31 (s, 
3H); 13C NMR (126 MHz, CDCl3) δ 174.6, 139.7, 134.8, 128.6, 128.5, 127.2, 117.1, 
65.7, 52.9, 41.9, 41.8, 41.4, 18.2 ; IR (Neat Film, NaCl) 3435, 3304, 3193, 3077, 2971, 
2936, 2809, 1664, 1489, 1451, 1418, 1381, 1361, 1345, 1260, 1202, 1169, 1104, 1085, 
1030, 990, 908, 875, 750 cm–1; HRMS (MM: ESI-APCI) m/z calc'd for C15H21N2O 
[M+H]+: 245.1648, found 245.1638; [α]D 25.0 –32.1 (c 0.90, CHCl3, 91% ee). 
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(S)-2-Allyl-1-benzyl-2-methylpiperazine (13) 
 
Ketopiperazine 12 (48.0 mg, 0.20 mmol) was taken up in THF (1.0 mL) and added 
dropwise to a stirred suspension of LiAlH4 (22.0 g, 0.59 mmol) in 1.0 mL of THF.  It was 
allowed to stir under Ar atmosphere at reflux for 16 hours.  The reaction mixture was 
then cooled to 23 ºC and 0.2 mL of water was added dropwise followed by 0.2 mL of 2 N 
NaOH aqueous solution and 0.6 mL of water.   It was allowed to stir for 20 minutes.  The 
reaction mixture was then transferred to a seperatory funnel using 10 mL of EtOAc.  The 
organic layer was washed with a saturated solution of Rochelle’s salt (1 x 10 mL) and 
then the organic layer was washed with brine (1 x 10 mL), dried with Na2SO4, and 
concentrated under reduced pressure to give 13 as a colorless oil.  99% yield.  Rf = 0.3 
(5% MeOH in CH2Cl2); 1H NMR (500 MHz, CDCl3) δ 7.28 (d, J = 7.5 Hz, 2H), 7.23 (t, J 
= 7.5 Hz, 2H), 7.15 (t, J = 7.2 Hz, 1H), 5.85 (ddt, J = 14.7, 10.2, 7.4 Hz, 1H), 5.06 – 4.97 
(m, 2H), 3.56 (d, J = 13.8 Hz, 1H), 3.42 (d, J = 12.4 Hz, 1H), 2.79 (d, J = 12.4 Hz, 1H), 
2.72 (dt, J = 6.8, 2.9 Hz, 2H), 2.55 (dd, J = 13.9, 7.4 Hz, 1H), 2.49 (d, J = 12.4 Hz, 1H), 
2.38 (ddd, J = 11.9, 5.7, 4.1 Hz, 1H), 2.33 – 2.22 (m, 1H), 2.08 (dd, J = 14.0, 7.4 Hz, 
1H), 1.04 (s, 3H); The signal of the NH was not detected; 13C NMR (126 MHz, CDCl3) δ 
140.6, 134.9, 128.6, 128.3, 126.7, 117.4, 55.6, 55.5, 53.5, 46.9, 46.8, 29.9; IR (Neat Film, 
NaCl) 3063, 3025, 2929, 2799, 1494, 1452, 1363, 1313, 1139, 1070, 1028, 991, 910, 822, 
727 cm–1; HRMS (MM: ESI-APCI) m/z calc'd for C15H23N2 [M+H]+: 231.1856, found 
231.1839; [α]D 25.0 –4.6 (c 0.625, CHCl3). 
Procedures for the Deprotection and Functionalization of α-Quaternary 
Piperazin-2-ones 
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(S)-3-Allyl-4-(4-methoxybenzyl)-3-methylpiperazin-2-one (14) 
 
Ketopiperazine 9c (25.0 mg, 0.07 mmol) was taken up in MeOH (1.5 mL) and H2O (1.5 
mL) and stirred with lithium hydroxide monohydrate (4.0 mg, 0.10 mmol) for 16 hours 
open to air.  Reaction mixture was then diluted with EtOAc and washed once with 
saturated aqueous sodium bicarbonate.  The aqueous layer was extracted with EtOAc (3 x 
10 mL) and the organic layers were combined, washed once with brine, dried with 
Na2SO4, and concentrated under reduced pressure on to silica. Deprotected 
ketopiperazine 14 was isolated as a white solid by flash column chromatography (SiO2, 
50% EtOAc in hexanes).  93% yield.  Rf = 0.3 (50% EtOAc in hexanes); 1H NMR (500 
MHz, CDCl3) δ 7.40 – 7.17 (m, 2H), 6.86 (d, J = 8.6 Hz, 2H), 6.34 (s, 1H), 6.00 (ddt, J = 
17.1, 10.3, 7.0 Hz, 1H), 5.24 – 4.98 (m, 2H), 3.92 (d, J = 13.5 Hz, 1H), 3.81 (s, 3H), 3.27 
(t, J = 9.7 Hz, 2H), 3.06 (dq, J = 10.8, 3.3 Hz, 1H), 2.83 (dd, J = 14.7, 6.5 Hz, 1H), 2.64 
(dd, J = 8.9, 3.4 Hz, 2H), 2.56 (dd, J = 14.6, 7.4 Hz, 1H), 1.37 (s, 3H); 13C NMR (126 
MHz, CDCl3) δ 174.7, 158.8, 134.9, 131.6, 129.8, 117.0, 113.8, 65.6, 55.4, 52.2, 41.8, 
41.7, 41.3, 18.2; IR (Neat Film, NaCl) 3202, 3073, 2935, 2833, 1667, 1611, 1511, 1488, 
1455, 1360, 1344, 1301, 1245, 1168, 1104, 1082, 1034, 989, 909, 824, 799, 731 cm–1; 
HRMS (MM: ESI-APCI) m/z calc'd for C16H23N2O2 [M+H]+: 275.1754, found 275.1730; 
[α]D 25.0 –21.3 (c 1.00, CHCl3). 
 
(S)-1,3-Diallyl-4-(4-methoxybenzyl)-3-methylpiperazin-2-one (15) 
 
Ketopiperazine 14 (13.0 mg, 0.05 mmol) was taken up in THF (0.5 mL) and stirred with 
sodium hydride (3.0 mg, 0.07 mmol) for 5 minutes at 0 °C. Then allyl bromide (0.01 mL, 
HN
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0.07 mmol) was added neat dropwise and the reaction was allowed to stir at 0 °C until 
TLC analysis indicated full consumption of the starting material. The reaction mixture 
was warmed to 23 °C and was then diluted with  5 mL od EtOAc and poured into 5 mL 
of water.  The aqueous layer was extracted with EtOAc (3 x 5 mL) and the organic layers 
were combined, washed once with brine, dried with Na2SO4, and concentrated under 
reduced pressure on to silica. Allylated ketopiperazine 15 was isolated as a colorless oil 
by flash column chromatography (SiO2, 20% EtOAc in hexanes). 65% yield.  Rf = 0.6 
(50% EtOAc in hexanes); 1H NMR (500 MHz, CDCl3) δ 7.27 (d, J = 8.5 Hz, 2H), 6.85 
(d, J = 8.6 Hz, 2H), 5.92 (ddt, J = 17.2, 10.2, 7.0 Hz, 1H), 5.82 – 5.66 (m, 1H), 5.19 – 
5.12 (m, 2H), 5.12 – 5.02 (m, 2H), 4.07 (dd, J = 15.0, 5.8 Hz, 1H), 3.96 – 3.83 (m, 2H), 
3.80 (s, 3H), 3.27 (ddd, J = 11.5, 10.0, 5.4 Hz, 1H), 3.22 (d, J = 13.4 Hz, 1H), 2.92 (dt, J 
= 11.4, 3.1 Hz, 1H), 2.86 (dd, J = 14.6, 6.6 Hz, 1H), 2.63 (tt, J = 7.7, 3.9 Hz, 2H), 2.52 
(dd, J = 14.5, 7.3 Hz, 1H), 1.35 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 172.0, 158.8, 
135.1, 132.9, 131.6, 129.8, 117.4, 116.9, 113.8, 65.7, 55.4, 52.4, 50.0, 46.7, 41.9, 41.7, 
18.2; IR (Neat Film, NaCl) 3072, 2932, 2834, 1716, 1641, 1611, 1512, 1485, 1456, 1381, 
1360, 1301, 1246, 1169, 1035, 990, 916, 826, 780, 756 cm–1; HRMS (MM: ESI-APCI) 
m/z calc'd for C19H27N2O2 [M+H]+: 315.2067, found 315.2097; [α]D 25.0 –16.6 (c 0.62, 
CHCl3). 
 
Ethyl (S,E)-4-(4-benzoyl-1-(4-methoxybenzyl)-2-methyl-3-oxopiperazin-2-yl)but-2-
enoate (16) 
 
Ketopiperazine 9c (20.0 mg, 0.05 mmol) was taken up in CH2Cl2 (0.5 mL) and stirred 
with trifluoroacetic acid (5.0 mL, 0.06 mmol) for 5 minutes at 23 °C. Then ethyl acrylate 
(60.0 mL, 0.53 mmol) was added neat dropwise followed by the addition of the o-tolyl-
NHC Hoveyda-Grubbs catalyst (3 mg, 0.005 mmol) and the reaction was allowed to stir 
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at 23 °C for seven days. The reaction mixture was concentrated under reduced pressure 
directly on to silica. Ketopiperazine 16 was isolated as a colorless oil by flash column 
chromatography (SiO2, 10% EtOAc in hexanes to 20% EtOAc in hexanes). 47% yield.  
Rf = 0.2 (20% EtOAc in hexanes); 1H NMR (500 MHz, CDCl3) δ 7.55 – 7.51 (m, 2H), 
7.51 – 7.45 (m, 1H), 7.43 – 7.36 (m, 2H), 7.26 (d, J = 8.5 Hz, 2H), 7.15 (dt, J = 15.5, 7.3 
Hz, 1H), 6.91 – 6.84 (m, 2H), 5.93 – 5.85 (m, 1H), 4.23 (q, J = 7.1 Hz, 2H), 3.92 (d, J = 
13.3 Hz, 1H), 3.88 – 3.82 (m, 1H), 3.81 (s, 3H), 3.58 (ddd, J = 12.3, 10.8, 4.4 Hz, 1H), 
3.35 (d, J = 13.4 Hz, 1H), 3.00 (ddd, J = 15.3, 7.3, 1.3 Hz, 1H), 2.92 – 2.84 (m, 1H), 2.79 
(ddd, J = 12.9, 10.8, 3.6 Hz, 1H), 2.72 (ddd, J = 15.3, 7.3, 1.3 Hz, 1H), 1.47 (s, 3H), 1.31 
(t, J = 7.1 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 174.5, 174.3, 166.3, 159.1, 144.3, 
136.2, 131.7, 130.2, 129.6, 128.3, 127.7, 124.1, 114.1, 67.2, 60.5, 55.4, 52.4, 45.1, 42.0, 
39.6, 18.5, 14.5; IR (Neat Film, NaCl) 2976, 2935, 2899, 2827, 1718, 1685, 1653, 1610, 
1512, 1448, 1366, 1269, 1245, 1222, 1159, 1035, 977, 934, 821, 727, 694 cm–1; HRMS 
(MM: ESI-APCI) m/z calc'd for C26H31N2O5 [M+Na]+: 473.2047, found 473.2046; [α]D 
25.0 –86.6 (c 0.62, CHCl3). 
 
(S)-3-Allyl-1-benzoyl-3-methylpiperazin-2-one (17) 
To a 20 mL scintillation vial was added ketopiperazine 9c (16.0 mg, 0.04 mmol), 2,3-
dichloro-5,6-dicyano-1,4-benzoquinone (19.0 mg, 0.08 mmol), 0.6 mL of CH2Cl2, 0.06 
mL of H2O, and a magnetic stir bar.  The reaction was allowed to stir for 1.5 hours under 
ambient conditions at which point there was full conversion of the starting material by 
TLC.  The reaction mixture was poured into 5 mL of saturated sodium bicarbonate and 
extracted with CH2Cl2 (4 x 5 mL).  The combined organics were washed once with brine, 
dried with Na2SO4, filtered and concentrated under reduced pressure.  Ketopiperazine 14 
was isolated as a white solid by flash column chromatography (SiO2, 5% MeOH in 
CH2Cl2).  75% yield.  Rf = 0.4 (10% MeOH in CH2Cl2); 1H NMR (500 MHz, CDCl3) δ 
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7.53 (dd, J = 8.3, 1.3 Hz, 2H), 7.51 – 7.44 (m, 1H), 7.43 – 7.35 (m, 2H), 5.86 – 5.71 (m, 
1H), 5.27 – 5.16 (m, 2H), 3.90 (dt, J = 12.6, 4.9 Hz, 1H), 3.79 (ddd, J = 12.7, 7.6, 4.9 Hz, 
1H), 3.36 – 3.14 (m, 2H), 2.77 (dd, J = 13.7, 6.8 Hz, 1H), 2.32 (dd, J = 13.8, 8.0 Hz, 1H), 
1.44 (s, 3H); the signal of the NH was not detected; 13C NMR (126 MHz, CDCl3) δ 
176.1, 174.6, 136.2, 132.6, 131.7, 128.3, 127.7, 120.4, 60.6, 48.2, 43.0, 38.6, 25.1; IR 
(Neat Film, NaCl) 3073, 2968, 2926, 2853, 1682, 1601, 1583, 1463, 1449, 1371, 1313, 
1285, 1212, 1177, 1152, 1111, 1071, 1022, 1001, 922, 795, 749, 727 cm–1; HRMS (MM: 
ESI-APCI) m/z calc'd for C15H19N2O2 [M+H]+: 259.1441, found 259.1432; [α]D 25.0 –71.8 
(c 0.87, CHCl3). 
 
 
Procedures for Preparation of Imatinib Analogs 
 (E)-3-(Dimethylamino)-1-(pyridin-3-yl)prop-2-en-1-one (SI14) 
3-Acetylpyridine (2.42 g, 20.0 mmol), N,N-dimethylformamide diacetal (3.7 g, 31.0 
mmol) and acetic acid (0.2 mL) were added to a 15 mL round-bottom flask equipped with 
a magnetic stirbar.  The reaction was heated to 95 °C for 3 hours.  It was then cooled to 
room temperature and poured into 10 mL of H2O.  The aqueous phase was extracted with 
CH2Cl2 (4 x 15 mL) and the combined organics were washed once with brine, dried with 
Na2SO4, and concentrated to yield SI14 as a red solid.  97% yield.  Product identity was 
confirmed by comparison to previously reported characterization data. 
 
4-(Pyridin-3-yl)pyrimidin-2-amine (SI15) 
 
N
NN
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N
O
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Pyridine SI14 (2.70 g, 12.5 mmol) was taken up in 12.5 mL of nBuOH along with 
guanidine nitrate (1.53 g, 12.5 mmol) and NaOH (0.50 g, 12.5 mmol).  The reaction 
mixture was refluxed for 20 hours.  Upon cooling to room temperature, pyrimidine SI15 
precipitated from the solution and was collected by filtration, washed once with water, 
and dried under reduced pressure. 76% yield.  Product identity was confirmed by 
comparison to previously reported characterization data. 
 
N-(2-Methyl-5-nitrophenyl)-4-(pyridin-3-yl)pyrimidin-2-amine (SI16) 
 
In a 50 mL round-bottom flask [Pd2dba3] (80.0 mg, 0.09 mmol), and rac-BINAP (130 
mg, 0.21 mmol) were combined in 13 mL of dioxane and heated to 100 °C for 30 minutes 
under argon atmosphere.  The resulting catalyst solution was cooled to room temperature 
and 2-bromo-1-methyl-4-nitrobenzene (376 mg, 1.74 mmol), prepared according to 
literature procedure,[7] SI15 (300 mg, 1.74 mmol), and Cs2CO3 (1.14 g, 3.48 mmol) 
suspended in 5 mL of dioxane was then added. The reaction mixture was then heated to 
100 °C for 24 hours.  After cooling to room temperature, the reaction mixture was 
concentrated under reduced pressure and nitro-arene compound SI16 was isolated by 
flash column chromatography (SiO2, 100% CH2Cl2 to 1% MeOH in CH2Cl2). 81% yield.  
Product identity was confirmed by comparison to previously reported characterization 
data. 
 
 
 
 
 
 
N
NN
NH
Me
O2N
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6-Methyl-N1-(4-(pyridin-3-yl)pyrimidin-2-yl)benzene-1,3-diamine (SI17) 
 
In a 100 mL round-bottom flask was added nitro-arene compound SI16 (190 mg, 0.62 
mmol) was dissolved in MeOH (50 mL).  Then 40.0 mg of 20% Pd on carbon was added.  
After sparging the reaction mixture with hydrogen for 15 minutes, the reaction mixture 
was allowed to stir overnight under one atmosphere of hydrogen.  The reaction mixture 
was carefully filtered through a plug of celite and concentrated to give aniline SI17.  99% 
yield.  Product identity was confirmed by comparison to previously reported 
characterization data. 
 
4-(Chloromethyl)-N-[4-methyl-3-[(4-(pyridin-3-yl)pyrimidin-2-yl]amino]-phenyl)-
benzamide (21) 
 
In a 15 mL round-bottom flask was added aniline SI17 (115 mg, 0.42 mmol), 4-
(chloromethyl)benzoyl chloride (78.0 mg, 0.42 mmol) and triethylamine (120 µL, 0.83 
mmol) were taken up in 4.2 mL of THF and allowed to stir for 3 hours at 23 ºC.  Reaction 
mixture was then poured into 5 mL of H2O and extracted with EtOAc (4 x 10 mL).  The 
combined organics were washed with brine, dried with Na2SO4, filtered, and 
concentrated.  Chloride 21 was isolated by flash column chromatography (SiO2, 100% 
N
NN
NH
Me
H2N
N
NN
NH
Me
N
H
O
Cl
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CH2Cl2 to 5% MeOH in CH2Cl2). 64% yield.  Product identity was confirmed by 
comparison to previously reported characterization data. 
 
(S)-4-[(3-Allyl-4-benzyl-3-methylpiperazin-1-yl)methyl]-N-(4-methyl-3-[(4-(pyridin-
3-yl)pyrimidin-2-yl)amino]phenyl)benzamide (18) 
 
In a 5 mL round-bottom flask chloride 21 (13.0 mg, 0.03 mmol), piperazine 13 (10.0 mg, 
0.04 mmol) and Cs2CO3 (0.020 g, 0.06 mmol) were taken up in 0.3 mL of dry DMF 
under Ar atmosphere and allowed to stir for 18 hours at room temperature.  Imatinib 
analog 18 was isolated directly by flash column chromatography (SiO2, CH2Cl2 to 3% 
MeOH in CH2Cl2).  42% yield.  Rf = 0.4 (10% MeOH in CH2Cl2); 1H NMR (500 MHz, 
CDCl3) δ 9.24 (dd, J = 2.2, 0.7 Hz, 1H), 8.70 (dd, J = 4.8, 1.6 Hz, 1H), 8.59 (d, J = 2.1 
Hz, 1H), 8.56 – 8.47 (m, 2H), 8.01 (s, 1H), 7.89 (s, 1H), 7.83 (d, J = 8.3 Hz, 2H), 7.46 (d, 
J = 8.4 Hz, 2H), 7.44 – 7.38 (m, 1H), 7.38 – 7.26 (m, 4H), 7.25 – 7.14 (m, 2H), 7.04 (s, 
1H), 5.93 – 5.71 (m, 1H), 5.11 – 4.92 (m, 2H), 3.66 – 3.41 (m, 3H), 2.95 (s, 2H), 2.88 (s, 
2H), 2.79 – 2.60 (m, 1H), 2.61 – 2.39 (m, 3H), 2.35 (s, 3H), 2.10 (dd, J = 13.9, 7.6 Hz, 
2H), 1.12 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 165.6, 162.9, 162.7, 160.7, 159.1, 
151.6, 148.6, 137.9, 137.9, 136.8, 135.1, 132.8, 130.9, 129.2, 129.0, 128.6, 128.4, 128.3, 
127.1, 126.7, 124.3, 123.9, 117.2, 115.5, 113.3, 108.5, 62.7, 56.2, 54.3, 53.1, 46.5, 36.6, 
31.6, 29.8, 17.8; IR (Neat Film, NaCl) 3292, 3054, 2923, 2853, 1666, 1579, 1551, 1528, 
1450, 1417, 1265, 1204, 1114, 1021, 801, 751, 703 cm–1; HRMS (MM: ESI-APCI) m/z 
calc'd for C39H42N7O [M+H]+: 624.3445, found 624.3456; [α]D 25.0 +2.3 (c 1.00, CHCl3). 
 
 
N
NN
NH
Me
N
H
O
N
N
Bn
Me
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N-(4-Methyl-3-[(4-(pyridin-3-yl)pyrimidin-2-yl)amino]phenyl)-4-(piperazin-1-
ylmethyl)benzamide (19) 
 
In a 5 mL round bottom flask was added chloride 21 (15.0 mg, 0.04 mmol), piperazine 
(11.0 mg, 0.13 mmol), Cs2CO3 (34.0 mg, 0.11 mmol), and 0.4 mL of dry DMF under Ar 
atmosphere and allowed to stir for 18 hours at 23 ºC.  Des-methyl imatinib (19) was 
isolated directly by flash column chromatography (SiO2, 1% MeOH in CH2Cl2 to 3% 
MeOH in CH2Cl2).  48% yield.  Product identity was confirmed by comparison to 
previously reported characterization data. 
 
 
(S)-N-(4-Methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)-4-((3-methyl-3-
propylpiperazin-1-yl)methyl)benzamide (20) 
 
Ketopiperazine 13 (22.0 mg, 0.10 mmol) was taken up in 3.2 mL of MeOH and 2 mL of 
glacial acetic acid in a 10 mL round bottom flask.  Pd on CaCO3 (5.00 mg) was added.  
The reaction mixture was then sparged for 15 minutes with H2 and allowed to stir under 
H2 atmosphere for 16 hours.  The reaction mixture was then carefully filtered through a 
plug of celite using MeOH and concentrated.  Chloride 21 (41.0 mg, 0.10 mmol) and 
Cs2CO3 (124 mg, 0.38 mmol) were then added along with 1 mL of dry DMF.  The 
N
NN
NH
Me
N
H
O
N
N
H
N
NN
NH
Me
N
H
O
N
N
H
Me
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reaction was allowed to stir under Ar atmosphere for 48 hours.  Imatinib analog 20 was 
isolated directly by flash column chromatography (SiO2, CH2Cl2 to 5% MeOH and ~1% 
NMe2Et in CH2Cl2). 4% yield.  Rf= 0.4 (15% MeOH and ~1% NMe2Et in CH2Cl2); 1H 
NMR (500 MHz, CDCl3) δ 9.24 (dd, J = 2.3, 0.8 Hz, 1H), 8.68 (dd, J = 4.8, 1.7 Hz, 1H), 
8.58 (d, J = 1.8 Hz, 1H), 8.54 – 8.42 (m, 2H), 8.03 (s, 1H), 7.85 (d, J = 8.3 Hz, 2H), 7.41 
(td, J = 6.3, 1.2 Hz, 3H), 7.31 (dd, J = 8.1, 2.0 Hz, 1H), 7.20 (d, J = 8.5 Hz, 1H), 7.16 (d, 
J = 5.2 Hz, 1H), 7.06 (s, 1H), 3.65 – 3.47 (m, 2H), 3.15 (t, J = 5.3 Hz, 2H), 2.68 (ddt, J = 
17.2, 11.3, 6.5 Hz, 2H), 2.39 (s, 2H), 2.34 (s, 3H), 1.77 (pd, J = 13.1, 4.8 Hz, 2H), 1.38 
(s, 4H), 1.21 (dtt, J = 12.8, 9.6, 4.6 Hz, 2H), 0.92 (t, J = 7.2 Hz, 3H); 13C NMR (126 
MHz, CDCl3) δ 165.3, 162.7, 160.5, 159.0, 151.4, 148.5, 141.8, 137.8, 136.5, 134.9, 
134.3, 132.6, 130.8, 129.0, 127.2, 124.3, 123.7, 115.4, 113.2, 108.4, 61.9, 59.8, 56.8, 
50.7, 39.8, 17.7, 16.4, 14.4; IR (Neat Film, NaCl) 3247, 2960, 2775, 2481, 2212, 1658, 
1581, 1532, 1447, 1418, 1318, 1289, 1046, 1019, 910, 801, 731 cm–1; HRMS (MM: ESI-
APCI) m/z calc'd for C32H38N7O [M+H]+: 536.3132, found 536.3138; [α]D 25.0 –8.4 (c 
0.17, CHCl3) 
 
Procedures for the Cell Viability Assay 
Human K562 chronic myelogenous leukemia (CML) cells were obtained from the 
American Type Culture Collection (ATCC). Cells were cultured in RPMI-1640 medium 
containing 10% fetal bovine serum (FBS) at 37 oC in 5% CO2. MTS assays were 
performed for cell viability as instructed by the supplier (Promega, Madison, WI). 
Briefly, cells (10000/well) were seeded in 96-well plates and exposed to compounds in a 
cell culture incubator in a dose-dependent manner for 48 h. DMSO was used as the 
vehicle control. Viable cell numbers were determined by tetrazolium conversion to its 
formazan and absorbance was monitored at 490 nm using an automated ELISA plate 
reader. Each experiment was performed in quadruplicate. Data are mean ± SD. 
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Determination of Enantiomeric Excess 
Entry Compound 
Assay Method and 
Conditions 
tR  
Major 
Isomer 
(min) 
tR 
Minor 
Isomer 
(min) 
% ee 
1 
 
SFC 
Chiralcel OD-H 
10% MeOH in CO2 
isocratic, 5.0 mL/min 
254 nm 
3.63 4.11 91% BzN
NBn
O
Me
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Entry Compound 
Assay Method and 
Conditions 
tR  
Major 
Isomer 
(min) 
tR 
Minor 
Isomer 
(min) 
% ee 
2 
 
SFC 
Chiralcel OJ-H 
10% MeOH in CO2 
isocratic, 5.0 mL/min 
254 nm 
3.40 4.00 52% 
3 
 
SFC 
Chiralpak AD-H 
10% MeOH in CO2 
isocratic, 3.0 mL/min 
210 nm 
6.77 9.00 90% 
4 
 
SFC 
Chiralcel OB-H 
3% MeOH in CO2 
isocratic, 2.5 mL/min 
210 nm 
10.11 9.17 94% 
5 
 
SFC 
Chiralcel OJ-H 
10% MeOH in CO2 
isocratic, 3.0 mL/min 
210 nm 
7.28 5.02 93% 
6 
 
SFC 
Chiralcel OJ-H 
10% MeOH in CO2 
isocratic, 3.0 mL/min 
210 nm 
7.81 4.41 87% 
7 
 
SFC 
Chiralpak AS-H 
10% MeOH in CO2 
isocratic, 2.5 mL/min 
210 nm 
3.66 3.41 81% 
BzN
NBz
O
Me
BzN
NPMB
O
Me
N
NBn
O
Me
F
O
N
NBn
O
Me
O
MeO
N
NBn
O
Me
OF
N
NBn
O
Me
BnO
O
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Entry Compound 
Assay Method and 
Conditions 
tR  
Major 
Isomer 
(min) 
tR 
Minor 
Isomer 
(min) 
% ee 
8 
 
SFC 
Chiralcel OJ-H 
10% MeOH in CO2 
isocratic, 3.0 mL/min 
210 nm 
5.36 4.57 97% 
9 
 
SFC 
Chiralcel OJ-H 
2% IPA in CO2 
isocratic, 2.5 mL/min 
210 nm 
3.95 3.43 85% 
10 
 
SFC 
Chiralcel OD-H 
1% IPA in CO2 
isocratic, 2.5 mL/min 
210 nm 
7.71 9.35 95% 
11 
 
SFC 
Chiralcel OJ-H 
2% IPA in CO2 
isocratic, 2.5 mL/min 
210 nm 
10.40 8.74 97% 
12 
 
SFC 
Chiralcel OJ-H 
20% IPA in CO2 
isocratic, 2.5 mL/min 
210 nm 
9.82 8.50 96% 
13 
 
SFC 
Chiralpak AS-H 
20% IPA in CO2 
isocratic, 2.5 mL/min 
210 nm 
3.14 3.84 98% 
BzN
NBn
O
Et
BzN
NBn
O
BzN
NBn
O OBn
BzN
NBn
O Ph
BzN
NBn
O
Me
Ph
BzN
NBn
O
Me
Cl
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Entry Compound 
Assay Method and 
Conditions 
tR  
Major 
Isomer 
(min) 
tR 
Minor 
Isomer 
(min) 
% ee 
14 
 
SFC 
Chiralcel OB-H 
10% IPA in CO2 
isocratic, 2.5 mL/min 
210 nm 
6.43 4.82 90% 
15 
 
SFC 
Chiralcel OB-H 
5% MeOH in CO2 
isocratic, 2.5 mL/min 
210 nm 
9.61 11.40 59% 
16 
 
SFC 
Chiralcel OJ-H 
2% IPA in CO2 
isocratic, 2.5 mL/min 
210 nm 
4.55 3.32 93% 
17 
 
SFC 
Chiralpak AS-H 
8% IPA in CO2 
isocratic, 2.5 mL/min 
210 nm 
3.21 2.16 82% 
18 
 
SFC 
Chiralpak AD-H 
40% IPA in CO2 
isocratic, 2.5 mL/min 
254 nm 
6.80 5.07 98% 
19 
 
SFC 
Chiralcel OJ-H 
0.2% IPA in CO2 
isocratic, 4.0 mL/min 
210 nm 
6.45 4.46 97% 
BzN
N
O
BzN
NBn
O Me
BzN
NPh
O
Me
BzN
NMe
O
Me
BzN
NBn
O
BzN
NBn
O
Me
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Entry Compound 
Assay Method and 
Conditions 
tR  
Major 
Isomer 
(min) 
tR 
Minor 
Isomer 
(min) 
% ee 
20 
 
SFC 
Chiralpak AD-H 
35% IPA in CO2 
isocratic, 3.5 mL/min 
210 nm 
8.58 7.58 87% 
21 
 
SFC 
Chiralcel OJ-H 
25% IPA in CO2 
isocratic, 2.5 mL/min 
210 nm 
8.12 9.85 99% 
 
 
 
BzN
NBn
O
Cl
BzN
NBn
O
Ph
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